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The overall goal of my work was to probe the structural biology of drug metabolite 
protein interactions and to correlate this with the negative side effects associated with many 
prescription drugs. More specifically, the focus was on the interactions of myoglobin (Mb), 
hemoglobin (Hb), a Clostridioides difficile nitroreductase (NR), and cytochrome P450 
BM3-HD with N-containing compounds. Using a combination of spectroscopy and X-ray 
crystallography, I was able to accomplish this goal. 
 In Chapter 2, the focus was on the formation of heme-nitroso adducts of Mb and 
Hb generated through oxidative and reductive pathways. While I initially predicted that 
heme-nitroso adducts would result from the reaction of Mb and Hb with nitro- and 
hydroxylamine-containing compounds, what actually resulted was the determination of a 
variety of products in addition to the predicted N-bound nitroso adducts. X-ray crystal 
structures of these products revealed that some of the compounds evaluated can indeed 
damage Hb through the formation of hemichromes that can be correlated with early stages 
of heme loss, which, downstream, may cause anemia. Additionally, we observed, for the 
first time, that two of the compounds evaluated are capable of S-nitrosating Hb at the 
Cys93 residue, an important contributor to the transportation of NO throughout the body. 
And finally, one of the X-ray crystal structures displays a ligand trapped in a Xe pocket, 
further demonstrating how large ligands can travel through the pockets within both Mb and 
Hb to reach the heme active site. The work presented in this chapter thus demonstrates a 
wide range of products that can result from the reaction of Mb and Hb with nitro- and 
hydroxylamine-containing compounds. 
xxxii 
 In Chapter 3, the focus was on C. difficile NRs responsible for metabolizing the 
antibiotic Mtz. Using UV-vis spectroscopy, I confirmed that a putative NR from C. difficile 
does in fact function as a Type I NR. Additionally, I solved its X-ray crystal structure, one 
of the first two reported from the hypervirulent C. difficile strain. The X-ray crystal 
structure also revealed a putative binding site for Mtz. The work in this chapter provides 
one of the first expression, purification, characterization and crystallization of a NR from 
the hypervirulent C. difficile strain. 
 The focus of Chapter 4 was on the interaction of cytochrome P450 BM3-HD with 
RNOs, imidazoles and arylhydrazines. Using spectroscopy, I showed that the interaction 
of RNOs with P450 BM3-HD result in N-bound products and the extent of product 
formation was dependent on alkyl group size. Imidazoles were found to bind through their 
N-atoms in a type II fashion. And finally, arylhydrazines were observed to initially bind in 
a type II manner, but with exposure to air, they formed -bonded aryl-iron complexes. The 
work in this chapter elucidates the identity of the products in the reaction of P450 BM3-
HD with RNOs, imidazoles and arylhydrazines. 
Together, the work presented in Chapters 2-4, shows how N-containing 
compounds and their metabolites interact with Mb, Hb, NRs and P450 BM3-HD.
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Chapter 1. Introduction 
Nitrogen is one of the most abundant elements on Earth, making up ~78% of the 
Earth’s atmosphere (in the form of N2), and it is the fourth most abundant element in the 
human body.1 Nitrogen is an important component of many endogenous compounds, such 
as DNA bases, amino acids, protein cofactors like flavin mononucleotide (FMN) and heme. 
Unsurprisingly, it is also found in many exogenous compounds and many of these are 
known to cause diseases or inhibit the natural functions of the proteins within the human 
body, emphasizing the relevance and importance of focusing on the interactions of these 
N-containing compounds with proteins. 
When a person is prescribed a medication, it is assumed that it is going to improve 
their health, however, most medications have minor and/or major side effects. As drugs are 
metabolized, their metabolites can interact with off-target proteins accounting for some of 
the side effects associated with them. For example, Adderall is prescribed for the treatment 
of attention deficit hyperactivity disorder (ADHD) and narcolepsy. A major component of 
Adderall is amphetamine, a N-containing compound. Amphetamine is metabolized in the 
liver by cytochromes P450 (P450s) and its metabolites are able to travel through the 
bloodstream, interacting with proteins such as hemoglobin (Hb) and myoglobin (Mb). 
Amphetamine metabolites have been shown to inhibit both P450s2-6 and a mutant form of 
Mb.7 Another N-containing drug, Chloramphenicol, is widely prescribed for the treatment 
of bacterial infections, but it has been shown to irreversibly interact with P450s and can 
displace O2 from Hb.
8, 9 
To combat the negative side effects associated with many prescription drugs, it is 
necessary to understand the biological chemistry of the drug metabolites. In Chapter 2, I 
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investigate the interactions of Hb and Mb with N-containing compounds. In Chapter 3, I 
characterize a new bacterial protein that metabolizes N-containing compounds. And 
finally, in Chapter 4, I study the products of the interactions of a model P450 with a series 





1.1 Heme protein interactions with N-containing compounds 
 
Simple nitrogen oxides (NOx) play an important role in the global nitrogen cycle 
(Figure 1.1).1 Various metalloproteins are involved in NOx interconversions, a major 
component of which are heme proteins (* in Figure 1.1). A substantial gap in knowledge 
is the structural biology of heme protein-NOx interactions. 
      
Figure 1.1. The nitrogen cycle and the enzymes (*heme proteins) involved (noted in 
grey). 
 
Myoglobin (Mb) and hemoglobin (Hb) are both mono heme-containing proteins 
found in the muscles (Mb) and blood (Hb). The primary role of Hb and Mb is dioxygen 
transport and storage, respectively. This role can be disrupted by the binding of other 
compounds, such as NOx derivatives, to the heme-Fe centers of these proteins. Nitroso 
(RNO, R=alkyl or aryl) compounds are NOx derivatives,  and they can form in vivo through 
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two potential routes – through the oxidation of amines (RNH2) and hydroxylamines 
(RNHOH) or through the reduction of nitro-containing (RNO2) compounds (Figure 1.2).
10 
  
Figure 1.2 The oxidative metabolism (left) of amines and hydroxylamines, and the 
reductive metabolism (right) of nitro compounds resulting in the nitroso derivatives 
where R = alkyl or aryl. 
 
Chapter 2 focuses on the structural biology of heme protein-nitroso derivatives. 
The metabolism of many commonly prescribed amine-containing (such as Adderall) and 
nitro-containing drugs (such as chloramphenicol) to their respective RNO derivatives are 
known, but much is still unknown about the nature of the resulting inhibitory heme-RNO 
interaction. The goal of this work was to characterize heme-RNO products generated by 
both the reductive and oxidative pathways. Presented in this work is the spectroscopic and 
crystallographic characterization of the products of the reactions between Mb and Hb with 
nitro- and hydroxylamine-containing compounds. I have determined high-resolution X-ray 
crystal structures of eight unique Mb/Hb-RNO complexes and collectively, these results 
illustrate the inhibitory and/or damaging effects that the formation of heme-nitroso 




1.2 Clostridioides difficile nitroreductase  
 
Metronidazole (Mtz), a nitro-containing drug, is prescribed for a multitude of 
bacterial infections, including Clostridioides difficile infection (CDI). CDI is caused by C. 
difficile, a bacterium that infects the lower gastrointestinal tract. According to the Center 
for Disease Control, each year, CDI causes ~29,000 deaths and costs the United States $1 
billion in excess medical costs.11 Mtz has remained the number-one recommended drug for 
the treatment of CDI, despite the recent emergence of Mtz-resistant C. difficile strains.12-18 
If nothing is done to combat this resistance, the death tolls and costs linked with CDI will 
continue to rise. 
In C. difficile, the nitroreductase (NR) enzymes are responsible for the metabolism 
of nitro-containing compounds including Mtz. Mtz is actually a prodrug that must be 
biochemically reduced for it to elicit its bactericidal effects. It is thought that the 
hydroxylamine metabolite is responsible for the bactericidal effects of Mtz, by inducing 
DNA breaks.19 Unlike Mb and Hb, which utilize a metal-containing heme to reduce nitro-
containing compounds, NRs utilize a non-metal-containing flavin mononucleotide (FMN) 
cofactor to reduce nitro-containing compounds (Figure 1.3). 
 
 
Figure 1.3 Reduction pathway of nitro compounds by Type I (air-insensitive) NRs. 
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Mtz resistance has been associated with NRs in both Bacterocides fragilis and 
Helicobacter pylori. 19-23 Additionally, in C. difficile, a mutation resulting in a truncation 
of a NR was found in both a resistant strain and sensitive strain with reduced susceptibility 
to Mtz, implicating NRs in Mtz resistance in C. difficile.24 Despite the importance of C. 
difficile NRs, no NRs from a pathogenic strain in C. difficile had been characterized prior 
to our work.25 In Chapter 3, I present the characterization of one of the first NRs from a 







1.3 Cytochrome P450 BM3-HD 
 
In humans, cytochromes P450 (P450s) are the primary protein responsible for 
metabolizing xenobiotics, making them an important family of proteins to study.26 P450s 
are a class of heme-containing mono-oxygenases that perform a multitude of functions, 
however they are best known for their role in drug metabolism.26, 27 Most human P450s are 
membrane-bound, making them difficult to work with and often necessitating the use of a 
model system. The P450 from Bacillus megaterium (P450 BM3) is commonly used as a 
model for human P450s, as it is not membrane-bound and is readily solubilized.28 P450 
BM3 possesses both a heme domain and a reductase domain. For the purposes of my study, 
only the heme domain was used (P450 BM3-HD). 
In Mb and Hb, the heme is coordinated by a proximal His, but in P450s, the heme 
is coordinated by a proximal Cys. Additionally, the active site of P450 BM3-HD, while 
similar to that of Mb and Hb, is significantly larger in volume. This large difference in 
volume accounts, in large part, for a much greater diversity of substrates (based on size) 
that can bind within the active site.  
The interaction of P450 BM3-HD with three different N-containing ligand sets 
(RNOs, imidazoles and arylhydrazines) is presented in Chapter 4. As shown in Figure 
1.2, RNOs are produced either through oxidative or reductive metabolism, and these RNOs 
can inhibit P450s by binding at their Fe centers.5, 29, 30 Imidazole groups are a common 
moiety in P450-targeted drugs, due to the high affinity of imidazoles for heme proteins.31, 
32 Arylhydrazines (ArNHNH2, Ar = aryl), components of drugs such as isoniazid, an 
antibiotic prescribed for tuberculosis, and hydralazine, a medication used to treat high 
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blood pressure and heart failure, can cause adverse health effects in humans such as cancer, 
liver damage, hemolytic anemia and reticulocytosis.33, 34 Much is still unknown about the 
nature of the products of the reactions between P450 BM3-HD and the above sets of 
compounds. My work presented in this chapter, using primarily UV-vis spectroscopy, 
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In mammals, the muscle protein myoglobin (Mb) and the blood protein hemoglobin 
(Hb) are associated with dioxygen (O2) storage and transport, respectively, by binding O2 
at their heme sites. Nitroso compounds (RNO; R = alkyl or aryl) can bind complementarily 
to the heme Fe since they are valence isoelectronic with O2.
1 RNO derivatives are produced 
either through oxidative metabolism of amines and hydroxylamines, or reductive 
metabolism of nitro compounds (Figure 2.1). 
Once present, RNO derivatives can bind to the Fe centers of the heme cofactors of 
various heme proteins and upon binding, can inhibit their normal functions. In fact, it has 
been shown that Hb has a higher affinity for RNOs than O2.
2 Although many amine- and 
nitro-containing  drugs  are  commonly  prescribed   for   various   medical  uses,  and  their 
 
*Reproduced in part, with permission, from (i) “Nitrosoamphetamine binding to 
myoglobin and hemoglobin: Crystal structure of the H64A myoglobin-nitrosoamphetamine 
adduct,” B. Wang, S.M. Powell, Y. Guan, N. Xu, L.M. Thomas, G.B. Richter-Addo. Nitric 
Oxide 2017, 67, 26-29 © 2017 Elsevier Inc. (ii) “Nitrosyl myoglobins and their nitrite 
precursors: Crystal structural and quantum mechanics and molecular mechanics theoretical 
investigations of preferred Fe–NO ligand orientations in myoglobin distal pockets,” B. 
Wang, Y. Shi, J. Tejero, S.M. Powell, L.M. Thomas, M.T. Gladwin, S. Shiva, Y. Zhang, 




metabolism to nitroso (RNO) derivatives are known, much is still unknown about the 
resulting heme-RNO interactions, increasing the importance of this work. 
 
Figure 2.1. The oxidative metabolism of amines/hydroxylamines and the reductive 
metabolism of nitro compounds resulting in the nitroso derivatives (R = alkyl or aryl). 
 
Mb is a ~17 kDa monomeric heme-containing protein located in the muscles of 
animals and its primary function is to store O2.
3 Human adult Hb, on the other hand, is a 
~64 kDa tetrameric protein consisting of two  and two  subunits, which is present in the 
blood and functions as an O2 transporter.
3 Each Hb subunit is ~16 kDa and contains a single 
heme cofactor. Although the  and  subunits of human adult Hb have only 43% sequence 
identity, their active site residues are conserved. Additionally, the globular shapes of the  
and  subunits are quite similar as well with an RMSD of 0.861 Å. Mb and the  subunit 
of Hb have only 25% sequence identity, but Mb and the  subunit of Hb have no significant 
sequence identity. Despite these low sequence identities, the overall globular folds of Mb 
and Hb consisting of -helices are highly conserved with an RMSD of 1.085 Å (for ) and 
1.139 Å (for ) (Figure 2.2). 
Much of the reason for the similarity in the interactions between substrates with Mb 
and Hb at their Fe centers can be correlated with their highly conserved active sites (Figure 
2.3). The proximal His in the F helix (H93 in Mb, H87 in  Hb and H92 in  Hb) 
 
16 
coordinates with the heme-Fe, holding it in place. The distal His in the E helix (H64 in Mb, 
H58 in  Hb and H63 in  Hb) has been shown to play an important role in the interaction 
of and entry of substrates and subsequent stabilization of binding to the heme.4-6 
 
Figure 2.2. Overlay of swMb (green, PDB id: 2MBW) with the  (magenta) and  
(cyan) subunits of Hb (PDB id: 3P5Q). 
 
Figure 2.3. Active site comparison of (A) swMb (PDB id: 2MBW) with (B) the Hb  
subunit and (C) the Hb  subunit (PDB id: 3P5Q). 
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 Due to the importance of the distal His residue and the hydrogen bonding 
stabilization it provides, our lab commonly uses four different Mb mutants – H64V, H64A, 
H64Q and V68A/I107Y (AY), to further examine its role in ligand binding and entry. In 
the H64V and H64A mutants, the bulky His residue is replaced with a smaller residue 
incapable of providing a hydrogen bond. Many species of mollusks7-9 and nematodes10 
have a hydrophobic residue (Val or Leu) at this site in their wild-type (wt) Mbs. The H64Q 
mutant introduces a more flexible residue that is capable of hydrogen bonding (both as an 
acceptor and donor). Some species of elephants11, 12, worms13, 14 and sharks15-17 have a Gln 
at this same position in their wt Mbs. The AY double mutant provides a second hydrogen-
bonding site in the interior region of the active site. 
 The goal of this study was to characterize representative nitroso adducts of Mb and 
Hb and to evaluate their potential physiological consequences. This was achieved by 
employing both the reductive and oxidative pathways for the generation of the nitroso 
products (Figure 2.1). For the reductive pathway, inorganic nitrite (NO2
-) and the organic 
nitro compounds metronidazole (Mtz) and chloramphenicol (CAM) were used (Figure 2.4, 
left). For the oxidative pathway, the organic hydroxylamine (RNHOH) compounds N-
phenylhydroxylamine (PhNHOH), N-hydroxyamphetamine (AmphNHOH), N-
tertbutylhydroxylamine (t-BuNHOH) and N-methylhydroxylamine (MeNHOH) were used 




Figure 2.4. Nitro-containing substrates (left) and hydroxylamine-containing substrates 
(right) used in this study. 
 
Nitrite has long been known to interact with Mb.18 Its role in meat curing19, 20, 
nitrification and the global nitrogen cycle21, and vasodilation22-24 have made it an important 
compound to study. While there is a large body of work on the chemistry of nitrite, prior 
to our group’s work, there had not been a systematic study of what factors influence the 
binding mode of nitrite in heme proteins such as Mb and Hb.4 Presented here is a study of 
the interaction of nitrite with the H64V mutant of sperm whale Mb (swMb). The related 
interaction with horse heart Mb (hhMb) was reported earlier by our group.5 Both sw and 
hhMb are used since they are easily obtained and high a high sequence identity with human 
Mb (84 - 88%).   
CAM and Mtz are widely prescribed antibiotics for the treatment of bacterial 
infections. CAM has been shown to interact irreversibly with cytochromes P450 (P450s) 
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and can displace O2 from Hb.
25, 26 Interactions of CAM with Mb had not yet been reported 
and there were no crystal structures of any heme protein with CAM prior to my work in 
this area. Mtz is used in the treatment of C. difficile infections and is typically metabolized 
by the bacterial nitroreductase enzymes (See Chapter 3). Mtz has been detected in blood 
samples of treated patients and its metabolites are known to be excreted through the liver.27 
This latter observation sparked my interest in the interaction of Mtz with heme proteins. I 
note that the interaction of Mtz with any heme protein had not been reported prior to this 
work. 
Aniline (PhNH2) is a widely used chemical in industrial settings and its toxic effects 
are well-documented.28-30 P450s are known to oxidatively metabolize aniline into 
PhNHOH. It has been confirmed that PhNHOH is the toxic form of aniline, and its presence 
leads to blood disorders such as methemoglobinemia and hemolytic anemia.31, 32 This is 
thought to be caused by the formation of nitrosobenzene (PhNO) upon reaction of 
PhNHOH with heme proteins.30 PhNO can also be formed from the nitrobenzene (PhNO2) 
precursor under reducing conditions.33 Given the importance of PhNHOH in human health, 
I became interested in further defining the products that result from its reactions with swMb 
and human Hb. 
Some commonly prescribed medications contain amphetamine (Amph), 
methamphetamine (methAmph), or a form of either. For example, Adderall®, a drug used 
to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy, is a combination 
of Amph and dextroamphetamine (d-Amph). Desoxyn® is a prescription methAmph for 
the treatment of obesity and ADHD. Despite their high medicinal value, Amph derivatives 
are known to have high potential for abuse.34 Because of this, Amph and methAmph are 
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classified by the U.S. Drug Enforcement Agency as Schedule II substances, meaning the 
drug has high potential for abuse and use may lead to severe dependence.34 Interactions of 
Amph and methAmph with heme proteins are an important component of their metabolism. 
Amph is oxidatively metabolized by P450s to generate AmphNHOH and other products1, 
while methAmph is oxidatively metabolized by P450s via aromatic hydroxylation and/or 
N-demethylation to generate Amph and AmphNHOH.35 Amph and AmphNHOH can also 
react with P450s to form inhibitory complexes36-40 as a result of the nitrosoamphetamine 
(AmphNO) metabolite forming an Fe-AmphNO complex.39, 41 AmphNHOH has been 
isolated as a metabolic intermediate of Amph in animals42, but surprisingly, formation of 
heme-AmphNO derivatives for Mb or Hb had not yet been reported prior to our lab’s 
work.43 Interestingly, it has been suggested by others that Mb- and Hb-AmphNO 
derivatives were unlikely to form due to the large size of AmphNO and the smaller-size 
heme distal pocket cavity in these proteins.44, 45 
 The t-BuNHOH and benzaldehyde compounds result from the decay of PBN (-
phenyl-N-t-butyl nitrone), a compound that has been shown to delay senescence in human 
lung fibroblasts, reverse the decay of mitochondria in rat livers and exert a neuroprotective 
effect in gerbils and rats.46 Atamna et al. used t-BuNHOH, MeNHOH and PhNHOH to 
show that PBN is unnecessary to exert these effects and that it is actually the N-
hydroxylamine metabolite of PBN that is responsible for these effects. They found that all 
N-hydroxylamines tested could exert these effects.46 Additionally, MeNHOH is used in the 
synthesis of biologically active azetidinones and isoxazoles, which make up the core of 
many prescription drugs.47 The interaction of N-hydroxylamines such as t-BuNHOH and 
MeNHOH with heme proteins has been studied in Mb and Hb48 as well as in 
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microperoxidase 8.44 MeNHOH has also been used to probe the reaction mechanism of 
P450s.49, 50 Prior to this work, however, there were no three-dimensional X-ray crystal 
structures characterizing the products of the interactions between Hb and t-BuNHOH and 
MeNHOH. 
 The work presented in this chapter provides both a spectroscopic and structural 
analysis of the heme-nitroso products of Mb and Hb formed through both the reductive and 




2.2 Materials and Methods 
2.2.1 Cloning of swMb 
The plasmid (pET-28a-wt) containing the gene for recombinant wild-type sperm 
whale myoglobin (wt swMb) was obtained from Professor Mario Rivera from the 
University of Kansas. The wt recombinant protein expressed from this plasmid as 
compared to native wt swMb, has an additional N-terminus Met and a mutation (D122N).6 
 All mutagenesis was performed in our lab by Dr. Bing Wang, using the Quick-
Change method (Stratagene), and transformed into E. coli DH5 competent cells. All 
mutants were confirmed by sequencing at Oklahoma Medical Research Foundation 
(OMRF) at the University of Oklahoma Health Sciences Center (OUHSC).  
 
2.2.2 Expression and purification of swMb proteins 
 The swMb proteins (wt and mutants) were expressed in E. coli BL21 (DE3). The 
proteins were purified as described by Springer and Sligar51 with slight modifications. The 
resuspended cells were lysed using an Emulsiflex in a buffer made up of 50 mM Tris, 1 
mM EDTA, pH 7.4 containing appropriate amounts of DNase, RNase and PMSF. A 60% 
ammonium sulfate precipitation was used first to remove contaminating proteins. This was 
followed by a 95% ammonium sulfate precipitation to obtain swMb. Overnight dialysis in 
a 1:9 glycerol to low salt buffer (100 mM potassium phosphate, 40 mM NaCl, pH 6) was 
used to remove ammonium sulfate. After centrifugation, the supernatant was loaded onto 
a CM52 cation exchange column equilibrated with low salt buffer. The sample was eluted 
using a linear salt gradient (40 mM – 1 M NaCl). Fractions containing the protein of interest 
(as judged by SDS-PAGE) were pooled for use in subsequent steps. 
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 It is common to obtain a mixture of apo and heme-bound protein from this 
procedure. Therefore, to obtain a homogenous mixture, heme reconstitution was performed 
following ion exchange column chromatography. Specifically, an excess of heme (15 mM 
dissolved in 0.1 M NaOH) was added dropwise into the pooled protein and the solution 
was left to stir overnight at 4 C. 
After centrifugation, the supernatant was concentrated using an Amicon ultra filter 
with a cutoff of 10 kDa (Millipore) and loaded onto a G75 gel filtration column equilibrated 
with 20 mM Tris, 1 mM EDTA, at pH 7.4. Pure protein fractions (as judged by SDS-
PAGE) were pooled and concentrated to either ~20 mg/mL for hanging drop crystallization 
or ~60 mg/mL for batch method crystallization. Protein concentration of wt and mutant 
(H64A, H64Q, V68A/I107Y) swMb was estimated using the absorbance of the heme 
(Soret band at  408 nm) using the extinction coefficient of ferric MbIII-H2O (188 mM
-
1cm-1). The exception to this is ferric H64V swMbIII which has a characteristic peak at 395 
nm in the Soret band with a corresponding extinction coefficient of 103 mM-1cm-1 at this 
wavelength.52 
If the resulting protein contained a mixture of oxidized (i.e., ferric) and reduced 
(i.e., ferrous) species typically indicated by a shoulder in the absorbance peak in the Soret 
region, an excess of potassium ferricyanide was added to fully oxidize the protein. The 
mixture was vortexed and then loaded onto a G25 desalting column to remove any excess 
potassium ferricyanide. Following this, the protein was again concentrated for use in 
further studies.  
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2.2.3 Isolation and purification of human Hb 
Human blood was obtained, with permission, from the Blood Bank at the 
University of Oklahoma Health Science Center in the form of packed cells. The bag of 
packed cells (~400 mL) was immediately placed on ice without direct contact in order to 
avoid degradation of the cells. OxyHb (ferrous HbII-O2) was isolated from the packed cells 
and purified following published protocols.3, 53 The concentration of the final, purified 
ferrous HbII-O2 was measured by UV-vis spectroscopy using its extinction coefficient of 
13.8 mM-1cm-1 at 541 nm and 14.6 mM-1cm-1 at 577 nm. The protein was flash frozen and 
stored at -80 C until needed. 
Prior to use, to ensure that all ferrous HbII-O2 was converted to metHb (ferric Hb
III-
H2O), 1.5 molar excess of potassium ferricyanide was added to thawed ferrous Hb
II-O2. 
After the solution turned from red to brown, indicating the reaction had taken place, the 
sample was loaded onto a G25 size exclusion column equilibrated with 50 mM sodium 
phosphate, pH 7.4 to remove any excess potassium ferricyanide. Brown-colored fractions 
were collected and combined. The concentration of ferric HbIII-H2O was measured by UV-
vis spectroscopy using its extinction coefficient of 9.1 mM-1cm-1 at 500 nm and 3.8 mM-
1cm-1 at 630 nm.3 
For all anaerobic experiments, the sample of HbII-O2 in buffer was degassed by 
bubbling nitrogen gas through it for ~30 min and transferred into an anaerobic MBraun 
chamber. After 4-5 days in the chamber, the ferrous HbII-O2 had converted to deoxyHb 
(ferrous HbII) as verified by UV-vis spectroscopy. The concentration of ferrous HbII was 
determined by UV-vis spectroscopy using its extinction coefficient of 133 mM-1cm-1 at 430 
nm and 12.5 mM-1cm-1 at 555 nm.3 
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2.2.4 Protein characterization 
All swMb proteins (wt and mutants) were expressed in E. coli. The wt and mutant 
proteins, except for the double mutant V68A/I107Y, were expressed in high yields (~100 
mg/L). The double mutant V68A/I107Y was expressed in significantly lower yields (~10 
mg/L). Following the CM52 column chromatography purification step, some impurities 
remained in the sample, but the final G75 column chromatography purification step 
removed these impurities. All swMb proteins were obtained in high purity (>90%) as 
evaluated by SDS-PAGE. Human oxyHb was also obtained at high purity following 
purification. 
 
2.2.5 UV-vis spectroscopy 
UV-vis measurements were carried out using a Hewlett-Packard 8453 
spectrophotometer. Quartz cuvettes (Starna Cells) equipped with screw caps were used for 
all experiments. All spectroscopy was carried out aerobically, unless otherwise noted. 
 
2.2.6 Synthesis of nitrosochloramphenicol 
 Nitrosochloramphenicol (CAMNO) was synthesized with the assistance of Dr. 
Erwin Abucayon following a published protocol.54, 55 The purity was checked by 1H NMR 
spectroscopy. The final product was dissolved in methanol for use in UV-vis studies.  
 1H NMR (400 MHz, CD3OD, 25 °C,   ppm): 7.77 (m, aromatic C-H), 6.16 (s, 
Cl2C-H), 5.06 (d, benzylic C-H), 4.62 (br, N-H), 4.10 (m, HCN-H), 3.70 (m, O-H), 4.78 




2.2.7 Synthesis of N-hydroxyamphetamine 
N-hydroxyamphetamine (AmphNHOH) was synthesized with the assistance of Dr. 
Erwin Abucayon following a published protocol.56 The purity was checked by 1H NMR 
spectroscopy, and the final product was dissolved in methanol for use in UV-vis studies. 
1H NMR (400 MHz, CDCl3, 25 °C,   ppm): 7.30 (m, 2H), 7.26 (s, residual CHCl3), 




Nitro compounds, sodium nitrite, CAM and Mtz, were purchased from Sigma 
Aldrich, Aldrich, and Fluka, respectively. Hydroxylamine compounds, PhNHOH, 
MeNHOH hydrochloride and t-BuNHOH hydrochloride, were purchased from Aldrich. 




2.2.9 UV-vis spectroscopy of swMb and Hb with nitro-containing compounds 
2.2.9.1 H64V swMb with nitrite 
UV-vis spectroscopy was used to monitor the reaction of H64V Mb and nitrite. An 
initial reading was taken of the starting ferric H64V MbIII (10  L of 20 mg/mL) in 2.5 mL 
of 0.1 M sodium phosphate buffer at pH 7.4. 5 L of sodium nitrite (1M) was then added 
to the cuvette to produce the ferric H64V MbIII-NO2 spectrum. Similar methods were 
followed to generate the spectrum of ferrous H64V MbII-NO from the addition of 5 L of 
sodium dithionite (1M) to the ferric protein followed by the addition of sodium nitrite.  
 
2.2.9.2 swMb and ferric Hb with Mtz and CAM 
UV-vis spectroscopy was used to monitor the reaction of ferric swMbIII-H2O (wt 
and mutants) and ferric HbIII-H2O with Mtz and CAM. An initial reading was taken of the 
starting ferric MbIII-H2O (5  L of 20 mg/mL) or ferric Hb
III-H2O (10  L of 25 mg/mL) 
in 2.5 mL of 0.1 M sodium phosphate buffer at pH 7.4. 5 L of sodium dithionite (1 M) 
was added to the cuvette to fully reduce the protein to ferrous deoxyMbII, and a reading 
was taken. 10-15 L of substrate (50 mg/mL CAM or 20 mM Mtz) was then added to the 
cuvette. Readings were taken at different time points during the course of the reaction to 
monitor its progress. 
 
2.2.9.3 deoxyHb with CAMNO 
UV-vis spectroscopy was used to monitor the anaerobic reaction of ferrous 
deoxyHbII with CAMNO. All buffers were degassed by bubbling nitrogen gas through 
them for ~30 min and brought into an anaerobic MBraun chamber prior to use. 
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Additionally, the cuvettes were capped prior to their transfer to the spectrometer in the 
main lab to prevent entry of O2. An initial reading was taken of the starting ferrous 
deoxyHbII (10  L of 25 mg/mL) in 2.5 mL of 0.1 M sodium phosphate buffer at pH 7.4. 
10 L of CAMNO (dissolved in methanol) was then added to the cuvette. Readings were 
taken at different time points during the course of the reaction to monitor its progress. 
 
2.2.10 UV-vis spectroscopy of swMb and ferric Hb with hydroxylamines 
2.2.10.1 swMb and ferric Hb with AmphNHOH 
UV-vis spectroscopy was used to monitor the reaction of ferric swMbIII-H2O (wt 
and mutants) and ferric HbIII-H2O with AmphNHOH. An initial reading was taken of the 
starting ferric MbIII-H2O (10  L of 20 mg/mL) or ferric Hb
III-H2O (10  L of 30 mg/mL) 
in 2.5 mL of 0.1 M sodium phosphate buffer at pH 7.4. Next, 10 L of AmphNHOH (200 
mM) was added. Readings were taken at different time points during the course of the 
reaction to monitor its progress. The anaerobic reaction of ferrous deoxyHbII with 
AmphNHOH was also performed following the same procedures; however, the cuvette 
was sealed, and all reagents were degassed by bubbling nitrogen gas through them for ~30 
min prior to use and added in an MBraun anaerobic chamber. 
In order to monitor the reversal of this reaction, ferric MbIII-H2O (in 0.1 M sodium 
phosphate buffer at pH 7.4) and solid AmphNHOH were mixed until the ferrous MbII-
AmphNO complex formed. 5 L of this reaction solution was added to 2.5 mL of 0.1 M 
sodium phosphate buffer at pH 7.4. Finally, 5 L of potassium ferricyanide (100mM) was 




2.2.10.2 Ferric Hb with PhNHOH, t-BuNHOH and MeNHOH 
UV-vis spectroscopy was used to monitor the reaction of ferric HbIII-H2O with 
PhNHOH, t-BuNHOH and MeNHOH. An initial reading was taken of the starting ferric 
HbIII-H2O (15  L of 30 mg/mL) in 2.5 mL of 0.1 M sodium phosphate buffer at pH 7.4. 
20 L of substrate (200 mM in the same buffer) was then added to the cuvette. Readings 
were taken at different time points during the course of the reaction to monitor its progress. 
 
2.2.10.3 wt swMb with PhNHOH 
UV-vis spectroscopy was used to monitor the reaction of ferric wt swMbIII-H2O (in 
0.1 M sodium phosphate buffer at pH 7.4) with PhNHOH. An initial reading was taken of 
the starting ferric wt MbIII-H2O (10  L of 20 mg/mL) in 2.5 mL of 0.1 M sodium 
phosphate buffer at pH 7.4. 10 L of substrate (200 mM in the same buffer) was then added 
to the cuvette. Readings were taken at different time points during the course of the reaction 
to monitor its progress. In order to monitor the reversal of this reaction, wt MbIII-H2O and 
solid PhNHOH were mixed for 10 min to generate ferrous wt MbII-PhNO. 5 L of this 
reaction solution was then added to 2.5 mL of 0.1 M sodium phosphate buffer at pH 7.4. 5 





2.2.11.1 H64V swMb-nitrite 
Crystals of ferric H64V swMbIII were grown as described by Phillips et al.57 Well 
solutions containing 2.52-3.2 M ammonium sulfate, 100 mM Tris-HCl, 1 mM EDTA, pH 
7.4 or 9.0 were used for the hanging drop vapor diffusion method. The drops contained a 
1:1 ratio of protein (28 mg/ml) to well solutions. The drops were seeded with crushed ferric 
H64A swMbIII-H2O crystals after an equilibration period of 8 h. The best crystals grew 
using 2.6-2.8 M ammonium sulfate at pH 9.0 after two weeks. Crystals were looped and 
placed into a 4 L drop of well solution containing 10% glycerol, and the drop was covered 
with mineral oil. A few grains of solid sodium nitrite were added into the drop and allowed 
to soak for up to 1 h. Crystals were harvested at different time points (15, 20, 25 and 30 
min) for X-ray diffraction data collection.  
 
2.2.11.2 H64Q swMb with Mtz 
The co-crystallization method was utilized. 75 L of ferric H64Q swMbIII-H2O (20 
mg/mL in 0.1 M sodium phosphate buffer at pH 7.4) was mixed with a few grains of solid 
Mtz and allowed to react for 15 min. A small of amount of solid sodium dithionite was 
then added to the mixture. Completion of the reaction was confirmed using UV-vis 
spectroscopy. Crystals were grown using the hanging drop vapor diffusion method as 
described by Phillips et al.57 The wells contained 2.56-2.76 M ammonium sulfate, 100 mM 
Tris-HCl, 1 mM EDTA, pH 7.4 or 9.0 and the drops contained a 1:1 ratio of protein-
reaction to well solution. The drops were seeded with crushed ferric H64A swMbIII-H2O 
crystals after an equilibration period of 6 h.  
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2.2.11.3 deoxyHb with CAMNO 
Anaerobic co-crystallization was utilized to crystallize [-FeII][-FeII-
SNO]{CAMNO}. In an MBraun anaerobic chamber, 2.5 mL of deoxyHb
II (30 mg/mL in 50 
mM sodium phosphate, pH 7.4) was mixed with a few grains of solid CAMNO and allowed 
to react for 20 min. Completion of the reaction was confirmed using UV-vis spectroscopy. 
Crystals were grown using the batch method as described by Safo and Abraham.53 
10.25x64 mm Monoject blood collection tubes (COVIDIEN) were used, and the tubes 
contained 0.5 M Fe citrate, 200 L of the deoxyHbII-CAMNO mixture and varying ratios 
of 3.6 M ammonium phosphate/sulfate.  
 
2.2.11.4 wt swMb with PhNHOH 
Crystallization of ferric wt swMbIII-H2O was performed using the hanging drop 
vapor diffusion method following the method of Phillips et al.57 Wells containing 2.52-3.2 
M ammonium sulfate, 100 mM Tris-HCl, 1 mM EDTA, pH 7.4 or 9.0 were used. The drops 
contained a 1:1 ratio of protein (20 mg/ml in 0.1 M sodium phosphate buffer at pH 7.4) to 
well solutions and were seeded after an equilibration period of 8 h. The best crystals grew 
using 2.56 M ammonium sulfate at pH 7.4. Crystals were looped into a 4 L drop of well 
solution containing 10% glycerol and the drop was covered with mineral oil. A small 
amount of solid PhNHOH was added into the drop and allowed to soak for up to 1 d. 




2.2.11.5 Ferric Hb with PhNHOH, MeNHOH, t-BuNHOH and AmphNHOH 
Co-crystallization was utilized to obtain crystals of the products resulting from the 
reactions of ferric HbIII-H2O with PhNHOH, MeNHOH, t-BuNHOH and AmphNHOH. 
The reactions were carried out in solution, and reaction completion was verified using UV-
vis spectroscopy prior to crystallization. For [-FeIII(H2O)][-Fe
III(His)2-SNO]{PhNO}, 2.5 
mL of ferric HbIII-H2O (30 mg/ml 50 mM sodium phosphate, pH 7.4) was mixed with 0.5 
mL of PhNHOH (200 mM in water) for 15 min prior to setting up crystallization. For [-
FeIII(H2O)][-Fe
II(MeNO)], 7.5 mL of ferric HbIII-H2O (30 mg/ml in 50 mM sodium 
phosphate, pH 7.4) was mixed with a few grains of solid MeNHOH for a total of 48 h; 
crystallization was set up at 2 h, 24 h, and 48 h. For [-FeIII(H2O)][-Fe
III(His)2]{t-BuNHOH}, 
7.5 mL of ferric HbIII-H2O (30 mg/ml in 50 mM sodium phosphate, pH 7.4) was mixed 
with a few grains of solid t-BuNHOH for a total of 5 d; crystallization was set up at 24 h, 
48 h and 5 d. For [-FeIII(H2O)][-Fe
II(AmphNO)], 2 mL of ferric HbIII-H2O (30 mg/ml in 
50 mM sodium phosphate, pH 7.4) was mixed with 0.5 mL AmphNHOH (90 mM in 
methanol) and allowed to react for one week prior to setting up crystallization. Crystals 
were grown using the batch method as described by Safo and Abraham.53 10.25x64 mm 
Monoject blood collection tubes (COVIDIEN) were used, and they contained 3.2 M Na/K 
phosphate buffer (pH 6.30, 6.47 or 6.81), 5 L toluene, and varying ratios of buffer to 






2.2.12 X-ray data collection 
 The diffraction data for all X-ray crystal structures, except that for [-
FeIII(H2O)][-Fe
III(His)2-SNO]{PhNO}, were collected at the University of Oklahoma 
Macromolecular Crystallography Lab (OU MCL) using a home source Rigaku MicroMax 
007HF microfocus X-ray generator coupled to a PILATUS 200K detector. The data was 
collected at 100 K with Cu K radiation ( = 1.54178 Å) from the generator operated at 
40 kV/30 mA. The diffraction data for [-FeIII(H2O)][-Fe
III(His)2-SNO]{PhNO}was 
collected at the Stanford Synchrotron Radiation Lightsource (SSRL) on beamline 9-2 ( = 
0.98 Å) equipped with a PILATUS 6M PAD detector. 
 
2.2.13 Data processing, structure solution and refinement 
The X-ray diffraction data for all structures were processed using HKL300058 and 
the resulting sca files were converted to mtz using Scalepack2mtz in the CCP4 program 
suite.59 PHASER MR (CCP4)60 was used to determine the initial phases. The model used 
for molecular replacement for all Mb structures (except H64V swMb-nitrite) was wt swMb 
(ferric MbIII-H2O) at 1.5 Å resolution (PDB ID: 2MBW) with the heme, water molecules 
and ligands removed from the structure. The model used for molecular replacement for all 
Hb structures was ferric R-state human aquomethemoglobin (ferric HbIII-H2O) at 2.0 Å 
resolution (PDB ID: 3P5Q) with the heme, water molecules, toluene and ligands removed 
from the structure. All refinements were performed using Refmac5 (CCP4).61 Models were 
rebuilt using COOT62 and validated using MolProbity63 to check for unusual residue 
conformations and contacts. Each structure is detailed below. 
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The figures for each structure were generated using Pymol.64 2Fo-Fc electron 
density maps were calculated by Fast Fourier Transform (FFT; CCP4).65 Fo-Fc electron 
density maps were generated by first deleting all ligands from the final pdb file of each 
structure. This pdb file was used to create a new Fc mtz file using SFall (CCP4). The Fc 
mtz file was used to generate the Fo-Fc electron density map using FFT. The resulting FFT 
map files were converted to ccp4 files and displayed in Pymol. 
 
2.2.13.1 Ferric H64V swMbIII-nitrite 
The model used for molecular replacement was wt swMb (ferric MbIII-H2O) at 2.0 
Å resolution (PDB ID: 2MGJ) with the heme, water molecules, and ligands removed from 
the structure. Ten initial cycles of restrained refinement were run with Refmac5, and the R 
factor decreased from 0.330 to 0.262. Ligands and water were added to the model based 
on the Fo-Fc electron density maps in the subsequent refinement cycles. Two sulfate anions, 
three glycerol and four nitrite anions (ligand id: NO2) were added to the model. Two 
conformations for the sidechain Val68 were modeled with 50% occupancy each. The final 
R factor and Rfree were 0.171 and 0.204, respectively. The final structure was deposited in 
the PDB with PDB accession number 6CF0. 
 
2.2.13.2 Ferrous H64Q swMbII-acetamide 
Ten initial cycles of restrained refinement were run with Refmac5, and the R factor 
decreased from 0.361 to 0.276. Ligands and water were added to the model based on the 
Fo-Fc electron density maps in the subsequent refinement cycles. Two sulfate anions, two 
glycerol and one acetamide (ligand id: ACM) were added to the model. The N-terminal 
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Met and the C-terminal residues Q152 and G153 were omitted due to lack of electron 
density. Two conformations for the sidechains Val68 and Lys133 were modeled with 50% 
occupancy each. The final R factor and Rfree were 0.204 and 0.221, respectively. 
 
2.2.13.3 [-FeII][-FeII-SNO]{CAMNO} 
Ten initial cycles of restrained refinement were run with Refmac5, and the R factor 
decreased from 0.451 to 0.331. Ligands and water were added to the model based on the 
Fo-Fc electron density maps in the subsequent refinement cycles. Four glycerol, eight 
sulfates and one CAMNO (ligand id: 5NF) were added to the model. The model for 
CAMNO was built in Phenix using REEL.66 The coordinates in a new pdb file and the 
topologies in a monomer library cif file were produced using eLBOW.67 CAMNO was 
modeled in with two different conformations of the terminal NO group at 50% occupancy 
each. Additional electron density around the -SH groups of the Cys93 residues were best 
modeled as S-nitroso moieties in these new S-nitrosocysteine derivatives (ligand id: SNC) 
and were modeled with two conformations at 50% occupancy each. The N-terminal 
residues Val1 and Lys2 in both  chains were omitted due to lack of electron density. Two 
conformations (50% occupancy each) were modeled for the sidechains Val96, Leu106 
and Ser131 in 1, for Ser84, Val96, Lys99 and Ser131 in 2, for Thr12, Leu32, Leu68, 
Leu78, Lys95, Asn108, and Asn139 in 1 and for Thr12, Glu26, Lys95, and Asn139 in 2. 




2.2.13.4 Ferrous wt swMbII-PhNO 
Ten initial cycles of restrained refinement were run with Refmac5, and the R factor 
decreased from 0.418 to 0.307. Ligands and water were added to the model based on the 
Fo-Fc electron density maps in the subsequent refinement cycles. One PhNO (ligand id: 
NBE) and one sulfate anion were added to the model. The N-terminal Met and the C-
terminal residues Asn152 and Gly153 were omitted due to lack of electron density. The 
final R factor and Rfree were 0.233 and 0.274, respectively. The final structure was deposited 
in the PDB with accession number 6M9N. 
 
2.2.13.5 [-FeIII(H2O)][-FeIII(His)2-SNO]{PhNO} 
Ten initial cycles of restrained refinement were run with Refmac5, and the R factor 
decreased from 0.349 to 0.291. Ligands and water were added to the model based on the 
Fo-Fc electron density maps in the subsequent refinement cycles. Five PhNO (ligand id: 
NBE) and one glycerol were added to the model. Additional electron density around the -
SH groups of the Cys93 residues were best modeled as S-nitroso moieties in these new S-
nitrosocysteine derivatives (ligand id: SNC) and were modeled with two conformations at 
50% occupancy each. Two conformations for each of the sidechains of 1-Glu26, 1-
Asp94, 1-His117, 2-Glu26, 2-His117 were modeled with 50% occupancy each. The 
C-terminal residues 144-146 in both  chains were omitted due to lack of electron density. 
The final R factor and Rfree were 0.201 and 0.248, respectively. The final structure was 





Ten initial cycles of restrained refinement were run with Refmac5, and the R factor 
decreased from 0.275 to 0.245. Ligands and water were added to the model based on the 
Fo-Fc electron density maps in the subsequent refinement cycles. Two MeNO ligands 
(ligand id: NSM), four glycerol, and two toluene molecules were added to the model. The 
C-terminal residues 140-141 in both  chains were omitted due to lack of electron density. 
Two conformations for the sidechains Thr38 in both  chains and Arg40 in both  chains 




Ten initial cycles of restrained refinement were run with Refmac5, and the R factor 
decreased from 0.314 to 0.264. Ligands and water were added to the model based on the 
Fo-Fc electron density maps in the subsequent refinement cycles. Four glycerol and four t-
BuNHOH molecules (ligand id: S9V) were added to the model. The model for t-BuNHOH 
was built in Phenix using REEL.66 The coordinates in a new pdb file and the topologies in 
a monomer library cif file were produced using eLBOW.67 The C-terminal residues 143-
146 in both  subunits were omitted due to lack of electron density. The final R factor and 
Rfree were 0.211 and 0.288, respectively. 
 
2.2.13.8 [-FeIII(H2O)][-FeII(AmphNO)] 
Ten initial cycles of restrained refinement were run with Refmac5, and the R factor 
decreased from 0.353 to 0.273. Ligands and water were added to the model based on the 
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Fo-Fc electron density maps in the subsequent refinement cycles. Two AmphNO ligands 
(ligand id: 3QM), one AmphNHOH molecule (ligand id: K7M) and one glycerol molecule 
were added to the model. The model for AmphNHOH was built in Phenix using REEL.66 
The coordinates in a new pdb file and the topologies in a monomer library cif file were 
produced using eLBOW.67 The C-terminal residues R141 in 1, 140-141 in 2 and 146 in 
2, as well as the N-terminal residues 1 in 1, and 1-2 in 2, were omitted due to lack of 
electron density. The final R factor and Rfree were 0.216 and 0.287, respectively. The final 
structure was deposited in the PDB with accession number 6M9P. 
 
2.2.14 UV-vis spectroscopy of crystals used in data collection 
In order to characterize the redox state of the crystals used to determine the crystal 
structures and to determine if X-ray exposure altered the redox state, UV-vis spectra of 
crystals were obtained after data collection. Specifically, after data collection, the crystal 
was removed from the goniometer and placed into a drop of 2-5 L of 100 mM sodium 
phosphate buffer at pH 7.4. Once the crystal was fully dissolved, the UV-vis spectrum was 




2.3.1 Interaction of H64V swMb and nitrite 
2.3.1.1 UV-vis of H64V swMb and nitrite 
Upon mixing ferric H64V swMbIII (0.1 M sodium phosphate at pH 7.4) with nitrite, 
no significant changes were observed in the UV-vis spectrum of the protein in either the 
Soret or Q regions. The peak in the Soret band remained at 395 nm and the peak in the Q 
band remained at 507 nm (Figure 2.5A). These results are consistent with the weak binding 
interaction between ferric H64A swMbIII-H2O and nitrite.
4 
Dithionite was added to ferric H64V swMbIII to reduce the protein to its deoxy form 
(ferrous deoxyMbII) and as a result, a shift in the Soret band from 395 nm to 433 nm 
(Figure 2.5B, C), and in the Q region from 506 nm to 559 nm (inset of Figure 2.5C) was 
observed. Next, nitrite was added and over time, a disappearance of the 433 nm peak and 
an appearance of a peak at 422 nm was observed in the Soret region (Figure 2.5B, C). 
Disappearance of the 559 nm peak and the appearance of two peaks at 548 nm and 584 nm 
within the Q band region also occurred (inset of Figure 2.5C). The reaction reached 
completion after ~35 min (inset of Figure 2.5B). These shifts are consistent with those 
observed for the reaction of nitrite with the ferrous deoxyMbII form of wt and the H64A, 






Figure 2.5. UV-vis spectroscopy of the reaction between ferric H64V swMbIII and nitrite. 
(A) Changes 30 min after the addition of nitrite. (B) Changes after the addition of 
dithionite followed by the addition of nitrite, additionally, a plot of  Abs(422-455) 
versus time. (C) UV-vis spectra of the three forms observed during the reaction of H64V 
swMb with nitrite, additionally, a zoomed in picture of the Q band region. Conditions: 






2.3.1.2 X-ray crystal structure of H64V swMbIII-NO2 
 Crystals of ferric H64V swMbIII-NO2 were obtained by soaking ferric H64V 
swMbIII crystals with nitrite (See Section 2.2.8.1). Crystals were harvested at 15, 20, 25, 
and 30 min time points. The best crystal for structure determination was obtained from a 
crystal harvested at the 30 min time point. The X-ray crystal structure of ferric H64V 
swMbIII-NO2 was solved to 1.64 Å resolution. Data collection and refinement statistics are 
displayed in Table 2-7. As shown in Figure 2.6, the nitrite is N-bound to the heme-Fe. 
This matches the ferric H64V hhMbIII-NO2 structure (See Discussion).
4 Note that Val68 is 
modeled in two orientations (50% occupancy each). 
 
 
Figure 2.6. X-ray crystal structure of ferric H64V swMbIII-NO2 showing only the active 
site. (A) Final model. (B) 2Fo-Fc map (contoured at 1 ). (C) Fo-Fc omit map (contoured 




2.3.2 Interactions of swMb and Hb with metronidazole and chloramphenicol 
2.3.2.1 UV-vis spectroscopic monitoring of the reactions of swMb with Mtz and CAM 
In all cases (wt and mutant), an initial reading was taken of ferric swMbIII-H2O. 
Dithionite was added to reduce the protein to its ferrous deoxyMbII form and as a result, 
shifts in the Soret band from ~409 to ~433 nm were observed for all proteins (Figure 2.7).  
 
Figure 2.7. UV-vis spectral changes during the reactions of (A) wt Mb with Mtz, (B) 
V68A/I107Y Mb with Mtz, (C) H64Q Mb with Mtz, and (D) H64Q Mb with CAM. 
Conditions: 0.1 M phosphate buffer, pH 7.4, [protein] = 2.0 µM, [dithionite] = 2 mM, 
[Mtz] = 350 µM or [CAM] = 600 µM. 
 
Mtz or CAM was then added to the reduced protein. In the case of ferric wt MbIII-
H2O in its reaction with Mtz, the peak in the Soret band shifted from 434 nm for the reduced 
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protein (ferrous deoxyMbII) to 420 nm (Figure 2.7A) and the reaction was complete after 
~20 min. Similar shifts were seen in the Soret bands for both ferric V68A/I107Y (432 to 
422 nm) and H64Q MbIII-H2O (434 to 421 nm) in their reactions with Mtz (Figure 2.7B-
C). The reaction of the H64Q Mb mutant with Mtz was complete after ~5 min, but the 
reaction with the V68A/I107Y Mb mutant took ~75 min to reach completion. Ferric H64Q 
MbIII-H2O was the only form of swMb that reacted with CAM, resulting in shifts in the 
Soret band from 434 to 419 nm (Figure 2.7D). This reaction was complete after ~10 min. 
The data in Table 2-1 summarizes the UV-vis spectral observations. The plots are not 
shown for the reactions that did not occur as the spectrum remained the same as the 
deoxyMbII spectrum.   
 
Table 2-1. Summary of the interaction of swMb with Mtz and CAM. 
Ligand wtMb H64A H64Q H64V V68A/I107Y 
Mtz 420 nm at 20 min No rxn 421 at 5 min No rxn 422 at 75 min 





2.3.2.2 UV-vis spectroscopic monitoring of the reactions of Hb with CAM, Mtz and 
CAMNO 
 The reactions of ferric HbIII-H2O with CAM and Mtz was performed and monitored 
with UV-vis spectroscopy, however no changes in the UV-vis spectra were observed, 
indicating lack of reaction. Previous work by Eyer, Lierheimer and Schneller26 
demonstrated that Hb interacts with the nitroso derivative of CAM, namely 
nitrosochloramphenicol (CAMNO), under anaerobic conditions. Therefore, UV-vis 
spectroscopy was used to probe the anaerobic interaction between ferrous deoxyHbII and 
CAMNO.  
After ~5 min, the Soret peak3 of ferrous deoxyHbII at 430 nm shifted to 422 nm 
(Figure 2.8), likely indicating the generation of a derivative with an Fe-bound ligand. The 
peak at 422 nm was stable for ~20 min. After that time, the peak slowly shifted to 406 nm, 
indicative of the formation of ferric HbIII implying limited stability of the Hb(CAMNO) 
derivative. 
 
Figure 2.8. UV-vis spectral changes during the reaction of ferrous deoxyHbII with 
CAMNO. Conditions: 0.1 M phosphate buffer at pH 7.4, [Hb] = 2.0 µM, final [CAMNO] 
= 600 µM. 
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2.3.2.3 The X-ray crystal structure of H64Q swMb with ACM 
Ferric H64Q swMbIII-H2O co-crystallized with Mtz yielded a product whose X-ray 
crystal structure did not match that of an Mtz-bound species. Instead, the new electron 
density at the heme site best matched that of acetamide (CH3C(=O)NH2; ACM). This 
structure was solved to 1.76 Å resolution at our home source (Figure 2.9). Data collection 
and refinement statistics are shown in Table 2-7. The diffraction data was obtained from 
crystals that grew in 2.60 M ammonium sulfate (see section 2.2.8.2). The crystallization 
conditions also contained Mtz and dithionite which resulted in the ring cleavage of Mtz, 
producing ACM (see later). As can be seen in Figure 2.9, ACM is bound to the Fe-center, 













Figure 2.9. X-ray crystal structure of ferrous H64Q swMbII-ACM showing only the 
active site. (A) Final model of the active site. (B) Fo-Fc omit map (contoured at 1.5 ). 







2.3.2.4 The X-ray crystal structure of the product resulting from reacting ferrous deoxyHbII 
with CAMNO 
The X-ray crystal structure of ferrous [-FeII][-FeII-SNO]{CAMNO}, resulting from 
the reaction of ferrous deoxy HbII and CAMNO, was solved to 1.75 Å resolution from 
diffraction data collected at our home source. Data collection and refinement statistics are 
displayed in Table 2-7. The diffraction data was obtained from crystals grown in final 
concentrations of 10.2 mM Fe citrate and 2.79 M ammonium phosphate/sulfate (See 
Section 2.2.8.3). The final tetrameric model as well as the active sites of one  and one  
subunit are shown in Figure 2.10. The  active site contains a fixed water molecule; 
however, the water does not lie perfectly above the Fe in the pocket and it is not coordinated 
with the Fe as it is too far away to form a direct Fe-H2O bond (3.5 Å, Figure 2.10B). This 
fixed water molecule is stabilized by hydrogen bonding with His58 (2.7 Å). On the other 





Figure 2.10. X-ray crystal structure of [-FeII][-FeII-SNO]{CAMNO}. (A) Overall 
tetrameric form. Final model of the active site of the 1 (B) and 1 subunit (C). 
 
In both active sites, the heme plane is not flat and is slightly distorted with the Fe 
center below the heme plane, indicating that the protein structure is likely in the T-state 
conformation. To further investigate this, we compared the 2 FG and 1 C interface, 
referred to as the signature “switch” region, of [-FeII][-FeII-SNO]{CAMNO} and of a 
known T-state Hb structure (PDB id: 1B86).68 The overall RMSD between the two 
structures is 0.381 Å and their switch regions align well, indicating that [-FeII][-FeII-
SNO]{CAMNO} is in the T-state conformation (Figure 2.11). Additionally, both the  and  




Figure 2.11. Comparison of the 12 interface of [-FeII][-FeII-SNO]{CAMNO} (green) 
and T-state deoxyHb (cyan; PDB id: 1B86). Analysis of the representative key residues 
show that the [-FeII][-FeII-SNO]{CAMNO} structure presented in this work is in the T-
state conformation. 
 
UV-vis spectral data were collected on the crystal used for the diffraction data 
collection to determine if any oxidation state changes had occurred during data collection. 
After X-ray data collection, the crystal was dissolved in 0.1 M sodium phosphate at pH 
7.4, and a UV-vis spectrum was obtained (Figure 2.12). A peak at 430 nm in the Soret 
region and a peak at 555 nm in the Q band region were observed. These peaks match the 
spectrum for ferrous deoxyHbII confirming that the [-FeII][-FeII-SNO]{CAMNO} complex 




Figure 2.12. UV-vis spectroscopy of the dissolved crystal of [-FeII][-FeII-
SNO]{CAMNO} after X-ray diffraction data collection. 
 
 Unfortunately, CAMNO was not observed in the active site of deoxyHb, but was 
found outside of the protein in the solvent region between the 2 and 2 subunits of the 
same tetramer (Figure 2.10A). The terminal nitroso group was modeled in two 
conformations (50% occupancy each). The CAMNO molecule is held in place through a 





Figure 2.13. (A) Fo-Fc omit map of the CAMNO molecule (contoured at 2.5 ). (B) The 
CAMNO hydrogen bonding network. 
 
Intriguingly, I found that Cys93 had been nitrosated in both  subunits (Figure 
2.14), resulting in S-nitrosothiol (SNO) derivatives. Unrestrained refinement was used to 
model in SNO in place of the -SH group of Cys93, and the SNO was modeled in two 
different conformations at 50% occupancy each. In both subunits, the two conformations 
are stabilized through hydrogen-bonding interactions with fixed waters and the nearby 





Figure 2.14. The environment surrounding the -SNO moiety in the overall [-FeII][-
FeII-SNO]{CAMNO} crystal structure and the Fo-Fc omit maps (contoured at 2.0 ) for 
the -SNO groups in both  subunits. 
 
 





Macromolecular crystallography is not normally able to distinguish between 
various forms of S-nitrosation. Hence, computational studies have been performed by 
others to predict bond lengths and bond angles of all the possible -SNO species (Table 
2-2).69-73 Table 2-3 displays the geometric parameters for the SNO groups present in [-
FeII][-FeII-SNO]{CAMNO}. These measurements are in agreement with calculations 
performed by Zhao and Houk69 that show within this crystal structure, conformation 1 of 
the nitrosated Cys93 is most likely the trans-SNO species and conformation 2 is most likely 
the thionitroxide radical (Cys-S-NH-O•). 
 
Table 2-2. Geometrical parameters of RSNO species as calculated by Zhao and Houk.69 
Bond distances are measured in Å and angles are measured in . 
 N-O S-N C-S SNO CSN CSNO 
cis-RSNO 1.194 1.791 1.804 118 104 0 
trans-RSNO 1.192 1.799 1.811 116 97 180 
RS-N•-OH 1.395 1.696 1.812 106 97 180 
RS-NH-O• 1.272 1.733 1.733 123 100 72 
RS-NH-OH 1.447 1.721 1.721 113 105 64 
 
Table 2-3. [-FeII][-FeII-SNO]{CAMNO} SNO parameters. Bond distances are measured 
in Å and angles are measured in . 
 N-O S-N C-S SNO CSN CCS CSNO 
1-1 1.25 1.56 1.84 121 107 111 163 
1-2 1.21 1.52 1.82 120 101 114 65 
2-1 1.25 1.58 1.83 122 112 116 173 





2.3.3 Interactions of wt swMb with PhNHOH 
2.3.3.1 UV-vis spectroscopy of wt swMb with PhNHOH 
Upon mixing ferric wt swMbIII-H2O with PhNHOH, changes in both the Soret and 
Q bands regions were observed using UV-vis spectroscopy. The peak in the Soret region 
shifted from 409 to 424 nm (Figure 2.16A-B). Additionally, the Q band peaks shifted from 
503 and 625 to 543 and 561 nm (inset of Figure 2.16B). These shifts are indicative of the 
formation of a ferrous derivative with an Fe-bound ligand. The reaction was essentially 
complete after ~15 min (inset of Figure 2.16A). To test the chemical reversibility of the 
reaction between ferric MbIII and PhNHOH, the oxidant potassium ferricyanide was added 
to the ferrous product MbII-PhNO in buffer (0.1 M sodium phosphate at pH 7.4). The 
original peaks in the Soret band and in the Q band were regenerated, indicating a return to 





Figure 2.16. Reactions of the ferric wt swMbIII-H2O with PhNHOH. (A) Changes after 
addition of PhNHOH and a plot of ΔAbs(422-511) against time. (B) UV-vis spectra of 
the two forms observed during the reaction and a zoomed-in picture of the Q band region. 
(C) Reaction of the ferrous wt swMbII-PhNO product with ferricyanide. Conditions: 100 
mM sodium phosphate pH 7.4, (A-B) [Mb] = 4.8 M, [PhNHOH] = 800 M; (C) [MbII-





2.3.3.2 X-ray crystal structure of wt swMbII-PhNO 
The X-ray crystal structure of PhNO bound to wt swMbII was solved to 1.75 Å 
resolution at our home source (Figure 2.17). Data collection and refinement statistics are 
shown in Table 2-7. The diffraction data was obtained from crystals of ferric MbIII that 
were soaked with PhNHOH for 30 min (see section 2.2.8.4). The resulting PhNO ligand 
was determined to be N-bound to the Fe which matches our UV-vis findings. As expected, 
the hydrophobic portion of the ligand is oriented towards the hydrophobic interior of the 
distal pocket in this protein. 
 
 
Figure 2.17. The final model and (A) 2Fo-Fc omit map contoured at 1 σ, and (B) the Fo-








2.3.4 Interactions of ferric Hb with RNHOH (R = Ph, Me, t-Bu) 
2.3.4.1 UV-vis spectroscopy of Hb with RNHOH (R = Ph, Me, t-Bu) 
UV-vis spectroscopy was used to monitor the reaction between ferric HbIII-H2O 
and the arylhydroxylamine PhNHOH (Figure 2.18). The Soret band shifted from 406 nm 
to 422 nm and in the Q band region, two new peaks at 540 nm and 560 nm appeared (Figure 
2.18B). The reaction was essentially complete after ~25 min (inset of Figure 2.18A). The 
changes in the spectra indicate that a ferrous derivative with a bound ligand likely formed. 
Interestingly, if the reaction was allowed to react for a longer period of time (~1 h), the 
solution within the cuvette became cloudy as a precipitate began to form possibly 
indicating degradation through irreversible hemichrome (bis-his coordinated heme) 
formation (see later).74  
 
Figure 2.18.  Reactions of ferric HbIII-H2O with PhNHOH. (A) Changes after addition of 
PhNHOH and a plot of ΔAbs(422-511) against time. (B) UV-vis spectra of the two forms 
observed during the reaction and a zoomed in picture of the Q band region. Conditions: 




UV-vis spectroscopy was used to monitor the related reaction between ferric HbIII-
H2O and MeNHOH (Figure 2.19). Over time, the Soret band at 405 nm shifted to 420 nm. 
In the Q band region, new peaks at 540 nm and 572 nm appeared (inset of Figure 2.19B). 
These shifts are indicative of the formation of a ferrous derivative with an Fe-bound ligand. 
However, the reaction never reached completion as can be seen in the Soret band region 
which still had partial 405 nm and partial 420 nm character. After approximately 1 h, the 
reaction reached its maximum extent of formation. Even after multiple days, the reaction 
did not ever reach completion (inset of Figure 2.19A). This may be an indication that 
MeNHOH was only reacting with either the  or  subunit and not both. 
 
Figure 2.19. Reactions of ferric HbIII-H2O with MeNHOH. (A) Changes after addition of 
MeNHOH and a plot of ΔAbs(418-525) against time. (B) UV-vis spectra of the two 
forms observed during the reaction and a zoomed-in picture of the Q band region. 
Conditions: 100 mM sodium phosphate pH 7.4, [Hb] = 3 M, [MeNHOH] = 1.6 mM 
 
UV-vis spectroscopy was used to monitor the reaction between ferric HbIII-H2O 
and t-BuNHOH (Figure 2.20). Only very subtle changes were observed during this 
reaction in the Soret band region. The peak at 406 nm decreased and slightly shifted to 409 
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nm. The largest differences were observed in the Q band region. The peaks at 500 and 630 
nm were replaced by peaks at 533 and 565 nm as well as a local minimum at 560 nm (inset 
of Figure 2.20). This pattern is consistent with the formation of a hemichrome containing 
a bis-histidyl coordinated ferric center.75 
 
Figure 2.20. UV-vis spectra of the reaction between ferric HbIII-H2O and t-BuNHOH as 
well as a zoomed-in picture of the Q band region. Conditions: 100 mM sodium phosphate 





2.3.4.2 The X-ray crystal structure of the product resulting from reacting ferric HbIII with 
PhNHOH 
Although UV-vis spectroscopy of the product generated from ferric HbIII and 
PhNHOH revealed the formation of the ferrous HbII-PhNO complex, attempted 
crystallization resulted in an unexpected degradation to ferric -hemichrome. The X-ray 
crystal structure of the product [-FeIII(H2O)][-Fe
III(His)2-SNO]{PhNO}was solved to 1.89 
Å resolution from diffraction data collected at the SSRL (Figure 2.21). Data collection and 
refinement statistics are shown in Table 2-7. The diffraction data was obtained from 
crystals grown in 3.2 M Na/K phosphate buffer at pH 6.81 (see Section 2.2.8.5). 
Differences were observed between the  and  active sites. In both  subunits, water was 
bound to the Fe at the active site. The 1 active site is shown in Figure 2.22. 
 
Figure 2.21. The overall 1.89 Å resolution X-ray crystal structure of [-FeIII(H2O)][-




Figure 2.22. The heme model and Fo-Fc omit map (contoured at 2σ) of water in the 1 
active site of [-FeIII(H2O)][-Fe
III(His)2-SNO]{PhNO}. 
 
In both  subunits, the heme is shifted towards the outside of the pocket, allowing 
for the formation of a hemichrome (Figure 2.23A-B). The movement of the heme out of 
the pocket left room behind the heme on the inside of the pocket, and two PhNO molecules 





Figure 2.23. (A) Overall view of the β1 chain, (B) the 2Fo-Fc map (contoured at 0.5 σ) of 
the hemichrome formed in the β1 subunit, (C) active site of the β1 subunit and (D) the 
Fo-Fc omit map (contoured at 1.5 σ) of PhNO in the β1 subunit. 
 
In both  subunits, one propionate group is fixed through H-bonding with nearby 
Lys66, but the orientation of the other propionate group differs between the two subunits 
(Figure 2.24). In 1, the other propionate group is flexible, but in 2, the other propionate 
has only one orientation, stabilized by H-bonding with a fixed water molecule (bottom 
right of Figure 2.24). The propionate groups in both  subunits are stabilized through H-
bonding interactions with fixed waters, Lys61 and His45 (top of Figure 2.24). Similar 






III(His)2-SNO]{PhNO} propionate interactions. 
 
Table 2-4 summarizes the stereochemical parameters of the hemichromes in this 
structure. The parameters measured include the tilt angle between the heme plane and the 
proximal (p) and the distal (d) histidine imidazole planes and the dihedral angle between 
the two imidazole planes () (Figure 2.25), as well as the bond angle N2im-Fe-N2im, and 
selected distance measurements. These parameters are within the reported ranges for 




Figure 2.25. Hemichrome measurements, p, d and . 
 
Table 2-4. [-FeIII(H2O)][-Fe
III(His)2-SNO]{PhNO} hemichrome parameters 





Cprox- Cdist (Å) 
Prox. Dist. 
1 90 80 177 72 2.2 2.1 12.7 
2 90 79 176 67 2.2 2.1 12.7 
 
Additionally, in both  subunits, the Cys93 sidechains were found to be nitrosated 
(Figure 2.26), resulting in S-nitrosothiol (SNO) derivatives. The -SNO group was modeled 
in place of the terminal -SH of Cys93 in two different conformations at 50% occupancy 
each (Figure 2.26) and each of these is stabilized through H-bonding interactions (Figure 
2.27). In both subunits, one -SNO conformation is stabilized by a Thr8 residue from the 
neighboring asymmetric unit. The other conformation is stabilized through a water H-





Figure 2.26. The environment surrounding the -SNO moieties in the overall 
[-FeIII(H2O)][-Fe
III(His)2-SNO]{PhNO} crystal structure (left) and the Fo-Fc omit maps 
(contoured at 2 ) for the SNO groups in both  subunits (right). 
 
 
Figure 2.27. H-bonding interactions between the Cys93-NO groups and the backbone 




Table 2-5 displays the geometrical measurements for the SNO groups of the S-
nitrosated ferric -hemichrome. Based on computational studies performed by others to 
predict bond lengths and bond angles of all the possible SNO species (Table 2-2)69-73, these 
measurements are in agreement with calculations performed by Zhao and Houk,69 that 
show within this crystal structure, the nitrosated Cys93 is most likely the thionitroxide 
radical species (Cys-S-NH-O•).  
 
Table 2-5. [-FeIII(H2O)][-Fe
III(His)2-SNO]{PhNO} SNO parameters. Bond distances are 
measured in Å and angles are measured in . 
 N-O S-N C-S SNO CSN CCS CSNO 
1-1 1.23 1.63 1.79 121 97 111 78 
1-2 1.21 1.63 1.80 116 92 111 88 
2-1 1.23 1.61 1.79 118 99 119 67 





2.3.4.3 The X-ray crystal structure of the product resulting from reacting ferric HbIII with 
MeNHOH 
Crystallization resulted in the formation of the [-FeIII(H2O)][-Fe
II(MeNO)] 
derivative. The X-ray crystal structure of this product was solved to 1.93 Å resolution from 
diffraction data collected at our home source (Figure 2.28). The structure was solved to 
1.93 Å resolution from diffraction data collected at our home source. Data collection and 
refinement statistics are shown in Table 2-7. The diffraction data was obtained from 
crystals grown in 3.2 M Na/K phosphate pH 6.30 in trays set at 2 h (See section 2.2.8.5). 
Differences were observed between the  and  active sites. In both  subunits, water was 
bound to the Fe at the active site and in both  subunits, MeNO was N-bound to the iron. 
The fact that the MeNO only reacted with one subunit is consistent with the UV-vis 
spectroscopy data obtained (see Figure 2.19). 
We then probed whether X-ray irradiation of the crystal altered the identity of the 
compound as it is common for Fe to undergo photoradiation. After X-ray data collection, 
the crystal was dissolved in buffer (0.1 M sodium phosphate at pH 7.4), and a UV-vis 
spectrum was obtained (Figure 2.29). Two peaks were seen in the Soret region at 406 and 
420 nm which is consistent with the solution UV-vis spectrum which suggested that MeNO 
only reacted with one subunit (Figure 2.19). The X-ray crystal structure confirms this, 





Figure 2.28. X-ray crystal structure of the [-FeIII(H2O)][-Fe
II(MeNO)] Hb derivative. 
(A) Overall tetrameric form. Final model of the active site and Fo-Fc omit maps 
(contoured at 2 ) of the 1 subunit (B) and 1 subunit (C). 
 
Figure 2.29. UV-vis spectroscopy of the dissolved crystal of the [-FeIII(H2O)][-
FeII(MeNO)] Hb derivative after X-ray diffraction data collection.  
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2.3.4.4 The X-ray crystal structure of the product resulting from reacting ferric HbIII with 
t-BuNHOH 
Crystallization resulted in the formation of the [-FeIII(H2O)][-Fe
III(His)2]{t-
BuNHOH} derivative. The X-ray crystal structure of t-BuNHOH in complex with human Hb 
was solved to 2.20 Å resolution from diffraction data collected at our home source (Figure 
2.30). Data collection and refinement statistics are shown in Table 2-7. The diffraction 
data was obtained from crystals grown in 3.2 M Na/K phosphate buffer at pH 6.30 (see 
Section 2.2.8.5). Differences were observed between the  and  active sites. In both  
subunits, water was bound to the Fe at the active site. The 1 active site is shown in Figure 
2.31. 
 
Figure 2.30. Overall X-ray crystal structure of the [-FeIII(H2O)][-Fe
III(His)2]{t-BuNHOH} 




Figure 2.31. Final model and Fo-Fc omit map (contoured at 1.75 σ) of water in the 1 
subunit active site of [-FeIII(H2O)][-Fe
III(His)2]{t-BuNHOH}. 
 
In both  subunits, the heme is shifted towards the outside of the pocket, allowing 
for the formation of a hemichrome (Figure 2.32A-B). The movement of the heme out of 
the pocket left room behind the heme on the inside of the pocket and a single t-BuNHOH 




Figure 2.32. (A) Overall view of the β1 chain, (B) the 2Fo-Fc map (contoured at 0.3 σ) of 
the hemichrome formed in the β1 subunit, (C) the active site of the β1 subunit and (D) the 
Fo-Fc omit map (contoured at 1.5 σ) of t-BuNHOH molecule in the β1 subunit. 
 
In both  subunits, the propionate groups are fixed through H-bonding with the 
nearby Lys66 and Lys59 residues (Figure 2.33, bottom). In the 1 subunit, however, the 
H-bonding interactions appear to be much weaker than those in the 2 subunit. The 
propionate groups in both  subunits are stabilized through H-bonding interactions with 
fixed waters and the nearby His58 and His45 residues (Figure 2.33, top). Similar 






III(His)2]{t-BuNHOH} propionate interactions. 
 
Table 2-6 summarizes the geometrical parameters of these -hemichromes from 
the reaction between ferric HbIII-H2O and t-BuNHOH. See section 2.3.5.2 and Figure 2.25 
for a description of the parameters measured. These parameters are within the reported 
ranges for other heme-based hemichromes.77, 78   
 
Table 2-6. [-FeIII(H2O)][-Fe
III(His)2]{t-BuNHOH} hemichrome parameters 





Cprox- Cdist (Å) 
Prox. Dist. 
1 79 84 174 78 2.4 2.4 13.0 
2 87 80 178 70 2.6 2.4 12.9 
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2.3.5 Interactions of swMb and Hb with AmphNHOH 
2.3.5.1 UV- vis spectroscopy of swMb with AmphNHOH 
UV-vis spectroscopy was used to monitor the reaction between ferric wt swMbIII-
H2O and AmphNHOH (Figure 2.34). The Soret band of the ferric wt Mb
III-H2O at max 
409 nm shifted slowly to 423 nm over a 24 h period, and new peaks in the Q band region 
at 543 and 576 nm also appeared (Figure 2.34B). These shifts are indicative of the 
formation of a ferrous MbII-RNO derivative. The reaction does not go to completion and 
in fact is only ~22% complete over this time period (calculated using OriginPro). Other 
ferrous MbII-RNO complexes display similar absorption bands.1,79 Once formed, this 
ferrous nitrosoalkane derivative is fairly stable in solution, showing only mild 
decomposition over time for the Mb products (~12% decomposition over 7 d) as judged by 
UV-vis spectroscopy. 
 
Figure 2.34. Reaction of ferric wt swMbIII-H2O with AmphNHOH. (A) Changes after 
addition of AmphNHOH and a plot of ΔAbs(425-555) against time. (B) UV-vis spectra 
of the two forms observed during the reaction and a zoomed-in picture of the Q band 
region. Conditions: 0.1 M phosphate buffer at pH 7.4, [Mb] = 2 M, final [AmphNHOH] 
= 80 M. 
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Additionally, the reactions of two other mutant ferric swMbs (H64Q and H64V) 
were evaluated with AmphNHOH using UV-vis spectroscopy (Figure 2.35). For ferric 
H64Q MbIII-H2O, the peak in the Soret region shifted from 409 nm to 424 nm and the peak 
in the Q band region at 503 nm disappeared as two peaks at 543 nm and 561 nm appeared 
(Figure 2.35A). Similarly, for ferric H64V MbIII, the peak in the Soret region shifted from 
395 nm to 425 nm and the peak in the Q band region at 504 nm disappeared as two peaks 
at 541 nm and 572 nm appeared (Figure 2.35B). The reaction was essentially complete 
after ~30 min for the H64Q Mb mutant and ~60 min for the H64V Mb mutant. 
 
Figure 2.35. UV-vis spectral changes during the reaction of AmphNHOH with ferric (A) 
H64Q and (B) H64V Mb mutants. A plot of ΔAbs(424-467) against time for the H64Q 
mutant (A) and ΔAbs(425-455) against time for the H64V mutant (B). Conditions: 0.1 M 
phosphate buffer at pH 7.4, [Mb] = 2 M, final [AmphNHOH] = 80 M. 
 
To test the chemical reversibility of the reaction between these ferric MbIII mutants 
and AmphNHOH, the oxidant potassium ferricyanide was added to the ferrous product 
MbII-AmphNO in buffer (0.1 M sodium phosphate at pH 7.4). The original peaks in the 
Soret region and in the Q band region reappeared, indicating a return their respective ferric 
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precursors (Figure 2.36). The time it took for the products to convert back to their ferric 
form varied. For wt Mb, the reaction was complete in ~40 min. The reaction was much 
quicker for the H64Q mutant (10 min) and especially for the H64V mutant (5 min). 
 
 
Figure 2.36. UV-vis spectroscopy of the reactions of ferrous (A) wt MbII-AmphNO, (B) 
H64Q MbII-AmphNO, and (C) H64V MbII-AmphNO with ferricyanide as well as a 
zoomed-in picture of the Q band region. Conditions: 100 mM sodium phosphate at pH 




2.3.5.2 UV-vis spectroscopy of ferric Hb with AmphNHOH 
The reaction of excess AmphNHOH with ferric HbIII-H2O in phosphate buffer at 
pH 7.4 results in spectral shifts (Figure 2.37) analogous to that of Mb. The Soret band 
shifts from 406 nm to 421 nm, and new bands at 541 and 559 nm appear, with a ~77% 
conversion occurring over a 4 h period (calculated using OriginPro). Once formed, this 
ferrous nitrosoalkane derivative is fairly stable in aerobic solution, showing no visible 
decomposition for the Hb derivative even after 3 d as judged by UV-vis spectroscopy. This 
experiment was also carried out under anaerobic conditions and similar results were seen. 
The reaction does reach completion faster under aerobic conditions, however. Under 
anaerobic conditions, the product is stable even after 6 d as judged by UV-vis spectroscopy. 
The reversal of this reaction using the oxidant potassium ferricyanide was attempted, 
however the reaction appeared to be irreversible. 
 
Figure 2.37.  UV-vis spectral changes during the reaction of ferric HbIII-H2O with 
AmphNHOH. (A) Spectra of the initial and final readings as well as a zoomed-in picture 
of the Q band region. (B) Time course and a plot of ΔAbs(421-414) against time. 
Conditions: 0.1 M phosphate buffer at pH 7.4, [Hb] = 12.5 µM, final [AmphNHOH] = 
100 µM.  
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2.3.5.3 The X-ray crystal structure of the product resulting from reacting ferric Hb with 
AmphNHOH 
Crystallization resulted in the formation of the [-FeIII(H2O)][-Fe
II(AmphNO)] 
derivative. The X-ray crystal structure of this product was solved to 2.15 Å resolution from 
diffraction data collected at our home source (Figure 2.38). Data collection and refinement 
statistics are shown in Table 2-7. The diffraction data was obtained from crystals grown in 
3.2 M Na/K phosphate buffer at pH 6.47 (see Section 2.2.8.5). Like that of the [-
FeIII(H2O)][-Fe
II(MeNO)] structure described earlier, differences were observed between 
the  and  active sites. In both  subunits (Figure 2.38B), water was bound to the iron at 
the active site, and AmphNO is N-bound to the Fe in both  subunits (Figure 2.38C). The 
hydrophobic portion of the AmphNO ligand is, as predicted, oriented towards the interior 




Figure 2.38. X-ray crystal structure of the [-FeIII(H2O)][-Fe
II(AmphNO)] Hb 
derivative. (A) Overall tetrameric structure. Final model of the active site and Fo-Fc omit 
maps of (B) the 1 subunit (contoured at 3 ) and (C) the 1 subunit (contoured at 2 ). 
 
 In order to determine the quaternary state of the full Hb tetramer, a comparison of 
the 2 FG and 1 C interface of representative structures was made (Figure 2.39). Based 
on this overall of the signature “switch” region, this [-FeIII(H2O)][-Fe
II(AmphNO)] 
structure (green in Figure 2.39) most closely matches that of R-state Hb (magenta in 





Figure 2.39. Comparison of the 12 interface of representative Hb structures. Analysis 
of the representative key residues show that the [-FeIII(H2O)][-Fe
II(AmphNO)] 
structure presented in this work is in the R-state. Green: [-FeIII(H2O)][-Fe
II(AmphNO)] 
(this work), Cyan: T-state deoxyHb (PDB id: 1B86), Magenta: R-state Hb(CO) (PDB id: 
1AJ9), Yellow: R2-state Hb(CO) (PDB id: 1BBB), Light Pink: R3-state Hb(CO) (PDB 
id: 1YZI) 
 
We further verified the Fe oxidation state the crystal by performing UV-vis on the 
dissolved crystal (Figure 2.40) after X-ray diffraction data collection. The spectrum 
displayed two peaks in the Soret band at 405 and 421 nm. The UV-vis spectrum of the 
precursor ferric HbIII-H2O has a max at 406 nm and in solution, upon reaction with 
AmphNHOH, the max shifts to 421 nm (see above). This supports the notion that the  
subunit has a ferric center bound with water (corresponding to the peak at 405 nm) and that 




Figure 2.40. UV-vis spectroscopy of the dissolved crystal of [-FeIII(H2O)][-


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.4.1 Interaction of H64V swMb with nitrite 
The X-ray crystal structure of ferric H64V swMbIII-NO2 revealed that the nitrite 
ligand was N-bound to the Fe center (Figure 2.41A). A similar result was obtained by a 
previous lab member, Dr. Jun (Eva) Yi, using H64V hhMb (Figure 2.41B).5 Based on the 
Fe-N(NO2) distances, the N-binding mode is much more defined in the sw derivative (2.1 
Å) than in the hh derivative (2.6 Å). In wt Mb, a H-bond is typically provided by the distal 
H64 residue, but in both ferric H64V MbIII-NO2 structures described here, the nitrite in the 
active site pocket is stabilized through a H-bonding network provided by fixed waters, 
which essentially take the place of the now-absent H64 residue.  
 
 
Figure 2.41. Comparison of the ferric H64V MbIII-NO2 X-ray crystal structures obtained 




The H64V Mb mutant is most closely related to the H64A mutant as both mutations 
lack a H-bond at position 64. The UV-vis spectrum of H64V swMb in reaction with nitrite 
(Figure 2.5) is similar to that from the reaction of H64A swMb and nitrite.4 However, the 
X-ray crystal structure of ferric H64A swMbIII-NO2, obtained by former lab member Dr. 
Bing Wang, displayed an O-bound NO2 moiety unlike the ferric H64V swMb
III-NO2 in 
which the NO2 was N-bound. This can be rationalized by the observation that the crystal 
structure of the precursor ferric H64A swMbIII-H2O adduct contains an Fe-bound H2O 
ligand80; thus, the O-bound nitrite appears to essentially replace another O-bound ligand 
(H2O). In contrast, however, the ferric H64V swMb
III structure does not reveal an Fe-bound 
H2O ligand
6, implying there may be a lower affinity for an added O-bound ligand such as 





2.4.2 Analysis of the reactions of swMb and Hb with Mtz and CAM 
2.4.2.1 Importance of H-bonding 
Our results, summarized in Table 2-1, suggest that a distal pocket H-bond is 
necessary for the reaction of both CAM and Mtz with ferric MbIII since neither CAM nor 
Mtz reacted with the H64A or H64V mutants. Mtz did react with ferric wt, H64Q and 
V68A/I107Y MbII suggesting that Mtz does not have a preference for a certain amino acid 
at position 64 but does require a H-bond in this location. Interestingly, CAM does not react 
with wt or V68A/I107Y Mb but does in fact react with the H64Q mutant. These results 
suggest that CAM has a preference for Gln over His in position 64. Since CAM is a larger 
substrate than Mtz (Figure 2.4), it likely requires a more flexible amino acid like Gln to 
allow CAM to enter the pocket. 
 
2.4.2.2 Analysis of the reaction of ferric H64Q swMbIII with Mtz 
Based on the UV-vis studies of the reaction of ferric H64Q MbIII-H2O and Mtz 
(Figure 2.7C), Mtz was predicted to be bound at the Fe-center of Mb in solution. However, 
after crystallization and solution of the X-ray crystal structure of this product, it was found 
that it was acetamide (ACM) that was bound instead. The reaction between Mb and Mtz 
was carried out under reducing conditions using sodium dithionite. Interestingly, sodium 
dithionite by itself can reductively activate Mtz, eventually leading to ring fission 
generating hydroxyethyl oxamic acid and ACM.81 Based on the X-ray crystal structure 
obtained, Mtz was likely cleaved by dithionite during the extended crystallization time 
period,81 and the crystals obtained were those from the contributing [Mb+ACM] reaction. 
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In the final structure (Figure 2.9), ACM was modeled as O-bound based on the crystal 
structure of a synthetic model obtained by a previous lab member, Dr. Nan Xu.82 
 
2.4.2.3 Analysis of the reaction between ferrous deoxyHbII with CAMNO 
 Prior to this work, there were no reported X-ray crystal structures of any heme 
protein in complex with CAM or its derivatives. Our original goal was to obtain such a 
complex containing a direct Fe-CAMNO interaction. Presented in this chapter is the heme-
protein crystal structure of Hb with an unbound CAMNO molecule in the crystal (Figure 
2.10 and Figure 2.13). The structure contains a weakly interacting H2O in the active site 
of the  subunit (Figure 2.10B) and no distal Fe-bound ligand in the  subunit active site 
(Figure 2.10C). This crystal was grown under anaerobic conditions and as shown by the 
analysis in Figure 2.11, the tetrameric structure is in the T-state. I note that the X-ray 
crystal structure of T-state deoxyHb (PDB id: 4HHB) also has a weakly interacting water 
in the  subunit and no Fe-bound ligand in the  subunit.83 The overall RMSD between 
ferrous T-state deoxyHbII and the [-FeII][-FeII-SNO]{CAMNO} structure is 0.381 Å 
indicating that CAMNO had very little effect on the overall protein structure. A primary 
important difference between the two structures is that in our [-FeII][-FeII-SNO]{CAMNO} 
structure, the Cys93 residues have been nitrosated (Figure 2.14). 
The crystal structure presented here is the first to show that CAMNO is capable of 
nitrosating Hb at the Cys93 residue. UV-vis studies show that CAMNO does react with 
Hb at the Fe center (our original intent), most likely forming an N-bound ligand (Figure 
2.8). Additionally, it is already known that CAMNO can displace O2 from Hb.
26 Further 
discussion of S-nitrosation is in section 2.4.7. 
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2.4.3 Analysis and comparison of the structures of the products from the reactions of 
ferric wt swMbIII and HbIII with PhNHOH 
Presented here is the structural demonstration of the interaction between swMb and 
PhNHOH yielding an N-bound FeII-PhNO adduct. The only other crystal structure of a Mb-
PhNO adduct is that from hhMb (PDB id: 2NSS) obtained by a former lab member Dr. 
Daniel Copeland. The two overall structures are very similar (RMSD of 0.452 Å), but with 
very slight differences in their active sites (Figure 2.42). For the residues in the active sites 
of the two structures, His64 is the residue that differs the most; a ~70° rotation ( swC1-
C2-hhC1) is observed. Due to this rotation in His64, the distance between the 
nitrosobenzene-O and His-N differs between the two (2.2 Å in swMb and 2.8 Å in hhMb). 
The orientation of the Fe-bound PhNO is similar in these two structures, with the 
hydrophobic phenyl group oriented towards the hydrophobic interior of the distal pocket. 
A unique feature of the previously determined ferrous hhMbII-PhNO structure was the 
presence of a second PhNO molecule (modeled in two conformations with 50% occupancy 
each) in the Xe1 pocket on the proximal side of the heme (bottom left side of Figure 2.42). 
Identified crystallographically in 1984,84 these Xe pockets (x4) have long been predicted 




Figure 2.42. Comparison of the active sites of ferrous swMbII-PhNO (cyan, this work) 
and hhMbII-PhNO (green, PDB id: 2NSS). 
 
 Only one other crystal structure of a heme protein in complex with PhNO has been 
reported, namely that of ferrous legHbII-PhNO, published in 1982.86 LegHb is found in 
leguminous plant nodules and is a monomeric protein. A comparison of the active site of 
our ferrous swMbII-PhNO structure was made with ferrous legHbII-PhNO (Figure 2.43). 
The orientation of PhNO is opposite in the two structures. In ferrous swMbII-PhNO, the 
phenyl group is oriented towards the inner, hydrophobic portion of the pocket, whereas in 
ferrous legHbII-PhNO, the phenyl group is oriented towards the outer, hydrophilic portion 
of the pocket. The likely reason for this difference is the position and orientation of the 
distal histidine. In swMb, the PhNO is stabilized through a H-bond with His64. However, 
this is not possible in the legHb structure. In ferrous legHbII-PhNO, His63 is oriented away 
from the heme pocket, making it very unlikely that PhNO would be able to form a H-bond 
with His63. In the X-ray crystal structure of ferrous legHbII-O2 (PBD id: 2GDM), the His63 
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residue is in a position closer to that of swMb His64. It is likely that in order for PhNO to 
enter the heme pocket and bind to the Fe center, legHb His63 had to rotate towards the 
exterior of the pocket. The rotation of His63 also creates a “larger” active site which may 
account for some of the reason why PhNO can be oriented towards the exterior of the 
pocket.  
 
Figure 2.43. Overlay of the active sites of ferrous swMbII-PhNO (cyan, this work) and 
legHbII-PhNO (magenta, PDB id: 1LH7). Residue identifiers are labeled black for Mb 
and grey for legHb. 
 
Unlike the reaction of ferric MbIII with PhNHOH to generate ferrous MbII-PhNO, 
the reaction of ferric HbIII with PhNHOH did not result in crystal containing an Fe-bound 
PhNO ligand. Instead, our crystallization conditions enhanced the formation of a 
hemichrome in the Hb  subunit (Figure 2.23). This unplanned result turned out to be 
quite advantageous, as it provided us with a physiologically important structure we could 
 
90 
not have otherwise obtained. The [-FeIII(H2O)][-Fe
III(His)2-SNO]{PhNO} structure was 
compared to a ferric HbIII-H2O crystal structure in order to assess the effects that the 
hemichrome formation had on the structure of the protein (Figure 2.44). The overall 
structures are quite similar (RMSD of 0.207 Å). However, large differences exist in the  
subunits. Formation of a hemichrome causes large movements in the F helix (residues 85-
100) as the proximal His92 residue is drawn further out of the pocket to stay coordinated 
to the heme Fe (Figure 2.23A). Additionally, there is a large shift (4.5 Å Fe1-Fe2) of the 
heme towards the outside of the pocket (Figure 2.23B). Further discussion of hemichrome 
formation is presented in section 2.4.8. 
 
 
Figure 2.44. Overlay of the β1 active site (A) and hemes (B) of a ferric HbIII-H2O (PDB 
id: 3P5Q; cyan) and [-FeIII(H2O)][-Fe




Not only did the reaction of ferric HbIII-H2O with PhNHOH result in a hemichrome 
formation, but our crystal structure is the first to show that the biologically relevant 
PhNHOH/PhNO species can serve as an “NO donor” to nitrosate Hb at the Cys93 
position. UV-vis studies show that PhNHOH does react initially with Hb at the Fe center, 
most likely forming an N-bound ligand such as that seen in swMb. We note that the 
nitrosation of the Cys93 residue induces flexibility in the C-terminal residues Lys144, 
Tyr145 and His146 of this structure, as was seen in a previously reported crystal structure 






2.4.4 Analysis of the [-FeIII(H2O)][-FeII(MeNO)] crystal structure 
 Presented here is the X-ray crystal structure of [-FeIII(H2O)][-Fe
II(MeNO)] 
formed through the oxidative pathway from reaction of ferric HbIII-H2O with MeNHOH 
(Figure 2.28). The only other reported X-ray crystal of MeNO in complex with Hb was 
published by a former lab member Dr. Jun (Eva) Yi.88 In her work, the Hb-MeNO adduct 
was formed through the reductive pathway from reaction of ferric HbIII-H2O with dithionite 
and MeNO2. Comparing these two structures, the overall RMSD is 0.204 Å. In Dr. Yi’s 
structure, MeNO is N-bound to the heme-Fe in both the  and  subunits ([-
FeII(MeNO)][-FeII(MeNO)]), but in my structure, MeNO is only N-bound to the heme-Fe 
in the  subunits and a water is bound in the  subunits ([-FeIII(H2O)][-Fe
II(MeNO)]) 
(Figure 2.45). Due to this observation, it is not surprising that there are very minor 
differences in the  active sites (Figure 2.45B), but larger differences exist in the  active 
sites (Figure 2.45A). In my structure, a water is held in place through H-bonding with 
His58 (2.9 Å). In Dr. Yi’s structure, the His58 residue swings out of the pocket ~16° ( 





Figure 2.45. Overlay of the heme sites of the α1 subunits (A) and β1 subunits (B) of the 
products formed from the reaction of ferric HbIII-H2O with dithionite and MeNO2 (cyan, 
PDB id: 4M4A) or with MeNHOH (magenta, this work). 
 
 The MeNO binding differences in these two structures can be explained by 
examining their UV-vis spectra. The reaction of ferric HbIII-H2O with dithionite and 
MeNO2 goes to completion.
88 However, the reaction between ferric HbIII-H2O and 
MeNHOH does not go to completion, even after multiple days (Figure 2.19). Therefore, it 
explains the observation that in Dr. Yi’s structure, MeNO is bound to Fe in both the  and 





2.4.5 Analysis of the [-FeIII(H2O)][-FeIII(His)2]{t-BuNHOH} crystal structure 
Hemichromes formed in the  subunits of ferric HbIII-H2O upon reaction with t-
BuNHOH (Figure 2.32). In many respects, the structure of the product was very similar to 
that formed from the PhNHOH reaction, but without S-nitrosation. To determine the effect 
that hemichrome formation had on the overall protein structure, the [-FeIII(H2O)][-
FeIII(His)2]{t-BuNHOH} crystal structure was compared to a ferric Hb
III-H2O crystal structure 
(Figure 2.46). The overall RMSD between the two structures is 0.229 Å, indicating that 
the two structures have high similarity. The main differences that exist between the two 
structures are within the  subunits. As can be seen in Figure 2.46A, hemichrome 
formation caused the F-helix (residues 85-100) to move as His92 was pulled further into 
the solvent channel to remain coordinated to the heme-Fe. The formation of a hemichrome 
also caused, similar to that seen from the PHNHOH reaction, a large shift of the heme (4.4 
Å Fe1-Fe2) out of the active site pocket (Figure 2.46B). Further discussion of hemichrome 




Figure 2.46. Overlay of the β1 active site (A) and hemes (B) of a ferric HbIII-H2O (PDB 
id: 3P5Q; cyan) and [-FeIII(H2O)][-Fe
III(His)2]{t-BuNHOH} (magenta, this work). This 







2.4.6 Analysis of the Mb- and Hb-AmphNO interactions 
2.4.6.1 E-helix movement allows for AmphNO binding  
Here we present the first X-ray crystal structure of the interaction between the bulky 
ligand, AmphNHOH, and human Hb. It was previously predicted that due to its smaller 
active site cavity, Hb would be unable to accommodate bulky ligands such as 
AmphNHOH/AmphNO in its active site.44, 45 To better understand how Hb was in fact able 
to accommodate AmphNHOH, our [-FeIII(H2O)][-Fe
II(AmphNO)] structure was aligned 
with that of ferric HbIII-H2O (PDB id: 3P5Q) as shown in Figure 2.47 and Figure 2.48. 
The overall RMSD of the two structures is 0.283 Å. The only significant differences 
observed between the structures are in the  subunits, more specifically in the E helix and 
EF corner regions. Within the active sites of the  subunits, very subtle differences are 
observed. The largest difference between the two active sites is the position of Val67, 
which was displaced by 3.5 Å (Figure 2.47). Val67 is part of the E helix and is not the 
only residue to undergo changes upon AmphNO binding to Fe (Figure 2.48). The E helix 
partially unravels, specifically between residues 65-76, inducing large shifts (1.5-8 Å in 
C), and allowing for the accommodation of the phenyl moiety of AmphNO which would 




Figure 2.47. Overlay of the 1 active sites of ferric HbIII-H2O (cyan, PDB id: 3P5Q) and 
[-FeIII(H2O)][-Fe
II(AmphNO)] (green, this work). 
 
 
Figure 2.48. Overlay of the 1 E helix of ferric HbIII-H2O (cyan, PDB id: 3P5Q) and [-
FeIII(H2O)][-Fe





2.4.6.2 Comparison of the structures of the  subunit of [-FeIII(H2O)][-FeII(AmphNO)] 
Hb and ferrous H64A swMbII-AmphNO 
We previously published the X-ray crystal structure of H64A Mb-AmphNO43 and 
have been unsuccessful to date in crystallizing any other (wt or mutant) ferrous swMbII-
AmphNO complexes. Despite this, the X-ray crystal structure of [-FeIII(H2O)][-
FeII(AmphNO)] presented here, provides us with very useful structural insight into the 
likely crystal structures of wt and other mutant swMb-AmphNO complexes. Alignment of 
the [-FeIII(H2O)][-Fe
II(AmphNO)]  chain with both ferric wt swMbIII-H2O (RMSD = 
1.183 Å, PDB id: 2MBW) and ferrous H64A swMbII-AmphNO (RMSD = 1.368 Å, PDB 
id: 5KD1), allowed us to further analyze the binding of AmphNO to Fe at the active sites 
of these heme proteins (Figure 2.49). 
 
Figure 2.49. Overlay of the active sites of ferric wt swMbIII-H2O (magenta, PDB id: 
2MBW), ferrous H64A swMbII-AmphNO (cyan, PDB id: 5KD1) and the 1 active site of 
[-FeIII(H2O)][-Fe
II(AmphNO)] (green, this work). Residue identifiers are labeled black 
for Hb and grey for Mb. 
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Just as that noted in the comparison of the 1 active site of [-FeIII(H2O)][-
FeII(AmphNO)] with ferric HbIII-H2O (Figure 2.47), the only significant difference in the 
active sites observed between ferrous H64A swMbII-AmphNO, ferric wt swMbIII-H2O  and 
the 1 active site of [-FeIII(H2O)][-Fe
II(AmphNO)], was the position of the Val67/Val68 
residues (Figure 2.49). The position of Val67 in the Hb structure is 2.6 Å (C) shifted from 
that of Val68 in both wt Mb and the H64A Mb mutant. A closer look at the E helix region 
(Figure 2.50) reveals that partial unraveling only occurred in the 1 subunit of the Hb 
structure. H64A Mb lacks a bulky residue at position 64 (analogous to H63 in Hb), 
therefore it was unnecessary for the E helix to unravel to accommodate Fe-bound AmphNO 
in the active site. Due to this lack of E helix movement, however, Val68 (analogous to 
Val67 in Hb) did not shift, which resulted in the orientation of the AmphNO phenyl group 
pointing towards the exterior of the active site pocket rather than towards the inside as 
observed in [-FeIII(H2O)][-Fe
II(AmphNO)]. 
From the UV-vis spectroscopy results, it was evident that AmphNO does bind to 
the Fe centers of active sites of wt, H64Q and H64V Mb. From the structural comparison 
in Figure 2.50, it appears that in order for AmphNO to bind in both wt and H64Q Mb, the 
E-helix likely shifts and partially unravels to move the distal Val similar to what was 
observed in [-FeIII(H2O)][-Fe
II(AmphNO)]. H64V Mb is more closely related to H64A 
Mb and therefore, AmphNO likely binds to the heme-Fe without movement of the E-helix, 






Figure 2.50. Overlay of the E helix region of ferric wt swMbIII-H2O (magenta, PDB id: 
2MBW), ferrous H64A swMbII-AmphNO (cyan, PDB id: 5KD1) and the 1 subunit of 
[-FeIII(H2O)][-Fe
II(AmphNO)] (green, this work). Residue identifiers are labeled black 






2.4.6.3 An AmphNHOH molecule in the  Xe2 pocket 
As with Mb, Xe pockets have long been predicted to be binding sites in Hb, 
contributing to ligand migration through the protein. Savino et al, identified 12 Xe sites in 
tetrameric Hb using X-ray crystallography.89 Molecular dynamics studies have mapped the 
possible cavities throughout Hb and shown the potential for ligands to reach the distal 
pocket by traveling through tunnels that match up with the Xe sites.90 Within the  subunits 
of our [-FeIII(H2O)][-Fe
II(AmphNO)] crystal structure, we have shown for the first time, 
the presence of a bulky ligand in one of these Xe pockets. 
Although water, and not an AmphNHOH derivative, was observed in the active site 
of the  subunits, molecules were found in the Xe2 pocket of both  subunits. In the 1 
subunit, a glycerol molecule was modeled in (Figure 2.51A-C) and in the 2 subunit 
(Figure 2.51D-F), an AmphNHOH molecule was modeled in to this site. The Xe2 pocket 
is surrounded by primarily hydrophobic residues, thus it is interesting that both glycerol 
and AmphNHOH were found in these sites. Glycerol interacts with a nearby fixed water 
and both the sidechain and mainchain of the Trp14 residue (Figure 2.51C). In the case of 
the AmphNHOH moiety, it is stabilized in this pocket through H-bonding with a nearby 
water which further H-bonds with the backbone C=O of the Gly18 and Trp14 residues 
(Figure 2.51F). 
Our UV-vis spectroscopy studies on the interaction of Hb with AmphNHOH43 
imply that AmphNO binds with both the  and  subunits, however this was not observed 
in our crystal structure. One of the possible pathways for ligands to travel to/from the distal 
pocket is through the Xe2 site.90 In our crystal structure, we have captured the AmphNHOH 
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in a temporary position as it was either traveling to or from the distal site where it can bind 
to the Fe-center. 
 
Figure 2.51. The crystal structure of the 1 subunit (A-C) and 2 subunit (D-F) from the 
[-FeIII(H2O)][-Fe
II(AmphNO)] Hb derivative. (A) The 1 chain displaying glycerol in 
the Xe2 pocket, (B) the Fo-Fc omit map (contoured at 2 σ) and (C) the nearest 
interactions in the 1 Xe2 pocket. (D) The 2 chain displaying AmphNHOH in the Xe2 
pocket, (E) the Fo-Fc omit map (contoured at 2 σ) and (F) the nearest interactions in the 





2.4.7. SNO formation in the Hb products 
S-nitrosation, namely the generation of S-nitrosothiols (SNOs) through the 
interaction of cysteines and NO, has been well-established as being important for the 
normal function of the human body.91, 92 Additionally, abnormal levels of SNOs have been 
associated with diseases such as diabetes, arthritis, strokes and even cancer.92, 93 
Furthermore, NO’s participation in vasodilation is thought to be supplemented by S-
nitrosation of Hb, where this may provide an additional route by which NO is transported 
from the lungs to the veins and arteries.94 S-nitrosation of proteins typically occurs at the 
site of exposed cysteine residues and there are a total of six cysteines per Hb tetramer, but 
only one that is accessible for S-nitrosation, namely the Cys93 residue.95 Consistent with 
this, in the structures presented above, S-nitrosation of Hb occurred only at the Cys93 
sites. 
There are currently a total of 28 S-nitrosated protein structures that have been 
deposited in the PDB. Of those, only one is of an S-nitrosated heme protein, namely that 
of SNO-Mb from blackfin tuna.96 A Hb-SNO structure was previously reported87; however, 
the structure was later reanalyzed and the “-SNO moiety” was determined to be the Cys-
S-N•-O radical.97 Presented in this work is the crystal structure of [-FeIII(H2O)][-
FeIII(His)2-SNO]{PhNO} displaying the presence of a thionitroxide radical (Cys-S-NH-O•) at 
the Cys93 position (Figure 2.14) and of [-FeII][-FeII-SNO]{CAMNO} displaying the 
presence of both the trans-SNO and thionitroxide radical at the Cys93 position (Figure 
2.26). 
 The mechanism by which NO is thought to be transported by Hb is linked with the 
allostery of the protein.91 In the T-state, the Cys93 residue is surface exposed, making it 
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easily accessible for S-nitrosation to produce SNO-Hb. Upon oxygenation, Hb transitions 
from the T to the R-state which moves the Cys93 residue into an internal inaccessible 
position, protecting the NO from being released. Finally, deoxygenation of SNO-Hb causes 
the protein to transition from the R-state back to the T-state, exposing the Cys93 residue 
and allowing the NO to be transferred to another protein. In this work, I was able to obtain 
a crystal structure of SNO-Hb in both the T and R-states. Of the two structures obtained, 
[-FeII][-FeII-SNO]{CAMNO} is in the T-state and [-Fe
III(H2O)][-Fe
III(His)2-SNO]{PhNO} 
is in a modified R-state. 
It is clear how Cys93 was nitrosated in the [-FeII][-FeII-SNO]{CAMNO} structure 
since in the T-state, the Cys93 residue is solvent exposed. The reason [-FeII][-FeII-
SNO]{CAMNO} was in the T-state is because the reaction took place anaerobically. However, 
it is important to note that SNOs cannot generally form under anaerobic conditions.98 This 
likely indicates the presence of traces of O2 during this reaction, which assisted in the SNO 
formation. The [-FeIII(H2O)][-Fe
III(His)2-SNO]{PhNO} crystal structure resulted from an 
aerobic reaction which generally favors the R-state. In the typical R-state, Cys93 is an 
internal residue, but in our [-FeIII(H2O)][-Fe
III(His)2-SNO]{PhNO} structure, due to 
hemichrome formation (see Section 2.4.8), the Cys93 residue becomes solvent exposed, 
making it possible for S-nitrosation to take place. 
 This work also showed for the first time that both the biologically relevant 





2.4.8. Hemichrome formation 
Hemichrome formation in physiology is significant, as hemichromes have been 
shown to lead to Heinz body formation in red blood cells leading to hemolysis and 
furthermore, hemolytic anemia.99, 100 Additionally, accumulation of hemichromes has been 
shown to contribute to thalassemias.101 Typically in tetrameric Hb, hemichromes are only 
formed in either the  or the  chains, but not both.77 In horse Hb, a hemichrome forms 
only in the  subunits102 and in arctic fish Hb, a hemichrome forms only in the  subunits.78 
Consistent with this notion of a single subunit ( or ) hemichrome formation, the reaction 
of ferric adult human HbIII-H2O with PhNHOH (Figure 2.23) or t-BuNHOH (Figure 2.32) 
produced hemichrome derivatives only in the  subunits. Although Mb has a more rigid 
distal pocket than Hb,74 hemichromes have in fact also been observed in Mb.103 
Observation of hemichromes only in the  chains of human tetrameric Hb is likely due to 
increased flexibility in the  chains of human Hb as compared to swMb and the  chains 
of human Hb. In general, there are two types of hemichromes, reversible (hemichrome I) 
and irreversible (hemichrome II). Without the addition of an exogenous ligand, over a 
period of seven months, human Hb only half converts to hemichrome I.100 This indicates 
that the hemichromes formed under our relatively short time periods are not an artifact of 
normal Hb degradation, but that the hemichrome formation is in fact caused by the addition 
of the PhNHOH and t-BuNHOH reagents. Although the reaction of both PhNHOH and t-
BuNHOH with human Hb resulted in  subunit hemichrome formation, there are only 
slight differences between the resulting structures (RMSD = 0.360 Å). 
As shown in Figure 2.44 ([-FeIII(H2O)][-Fe
III(His)2-SNO]{PhNO}) and Figure 
2.46 ([-FeIII(H2O)][-Fe
III(His)2]{t-BuNHOH}), the hemes in the β subunits of both structures 
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are laterally displaced out of the heme pockets, in addition to that observation of large 
movements in the proximal F helix (residues 85-100) regions, in order to accommodate 
hemichrome formation. The β-hemes in both structures have translated and rotated, ~4.4 – 
4.5 Å (Fe1-Fe2) and 30°, respectively, out of the heme pocket resulting in bis-coordination 





FeIII(His)2]{t-BuNHOH}, is shown in Figure 2.52. 
 
 
Figure 2.52. Overlay of the β1 active sites (A) and hemes (B) of ferric HbIII-H2O (cyan, 
PDB ID: 3P5Q), [-FeIII(H2O)][-Fe
III(His)2-SNO]{PhNO} (green, this work) and [-
FeIII(H2O)][-Fe
III(His)2]{t-BuNHOH} (magenta, this work). 
In order to determine the quaternary state of the full Hb tetramer, a comparison of  
the 2FG and 1C interface, referred to as the signature “switch” region, is made.68 The 
comparison is made using representative X-ray crystal structures in the R (PDB id: 1AJ9), 
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RR3 (PDB id: 3D17), R3 (PDB id: 1YZI), RR2 (PDB id: 1MKO) and R2 (PDB id: 1BBB) 
conformations. The quaternary structures of both [-FeIII(H2O)][-Fe
III(His)2-SNO]{PhNO} 
and [-FeIII(H2O)][-Fe
III(His)2]{t-BuNHOH} appear to be closest to the R conformation. In 
the case of [-FeIII(H2O)][-Fe
III(His)2-SNO]{PhNO}, it has an RMSD of (i) 0.7 Å with the 
R conformation, (ii) 1.0 Å with both the RR3 and R3 conformations, and (iii) 1.2 and 1.7 
Å with the RR2 and R2 conformations, respectively. For [-FeIII(H2O)][-Fe
III(His)2]{t-
BuNHOH}, it has an RMSD of (i) 0.6 Å with the R conformation, (ii) 1.8 Å with the R2 
conformation, (iii) 1.4 Å with the R3 conformation, (iv) 1.1 Å with the RR2 conformation, 




III(His)2]{t-BuNHOH} are similar 
to the R conformation of Hb, there are significant localized structural differences, primarily 
in the β subunits as a result of the hemichrome formation. Due to movement of the 
respective F helices, the His97 residues in both [-FeIII(H2O)][-Fe
III(His)2-SNO]{PhNO} 
and [-FeIII(H2O)][-Fe
III(His)2]{t-BuNHOH} have moved out of their characteristic classical 




Figure 2.53. Comparison of the signature switch regions of [-FeIII(H2O)][-Fe
III(His)2-
SNO]{PhNO} (green, this work), [-Fe
III(H2O)][-Fe
III(His)2]{t-BuNHOH} (magenta, this 
work) and R-state Hb (grey, PDB id: 1AJ9). 
 
The heme pocket is, in part, formed by the F-helix/FG-corner and C-helix/CD-
corner/E-helix/EF-corner, and hemichrome formation caused large movements in these 
regions. Large backbone movements of the F-helix/FG-corner residues 85-100 occurred in 
both [-FeIII(H2O)][-Fe
III(His)2-SNO]{PhNO} (1.5 – 6.8 Å) and [-Fe
III(H2O)][-
FeIII(His)2]{t-BuNHOH} (1.4 – 7.1 Å), causing unwinding of residues 93-96 in the F helices as 
shown in Figure 2.54. The surrounding heme environment comprised of residues 39-76 
(C-helix/CD-corner/E-helix/EF-corner) also show significant positional differences 
between the structures (~1-1.5 Å; Figure 2.55). Residues 41-46 of the CD-corner, and 
residues 59, 62, 63, 66, 67, 73-75 of the E-helix moved the most in [-FeIII(H2O)][-
FeIII(His)2-SNO]{PhNO}, whereas residues 41-43 and 46 of the CD-corner, and residues 59, 






Figure 2.54. Comparison of the F-helix region (residues 85-100) of [-FeIII(H2O)][-
FeIII(His)2-SNO]{PhNO} (green, this work), [-Fe
III(H2O)][-Fe
III(His)2]{t-BuNHOH} 
(magenta, this work) and R-state Hb (grey, PDB id: 1AJ9). 
 
Figure 2.55. Comparison of the C-helix/CD-corner/E-helix/EF-corner (residues 39-76) of 
[-FeIII(H2O)][-Fe
III(His)2-SNO]{PhNO} (green, this work), [-Fe
III(H2O)][-Fe
III(His)2]{t-
BuNHOH} (magenta, this work) and R-state Hb (grey, PDB id: 1AJ9). 
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 In summary, the reaction of PhNHOH and t-BuNHOH with Hb resulted in 
hemichrome formation in the  subunits. Hemichrome formation caused movement of the 
heme and secondary structures that make up the heme pocket and resulted in a modified 
R-state structure. More importantly, this movement of the heme out of its natural position 
within the pocket displays an early stage of heme loss, which eventually can lead to disease 





Presented in this chapter are the reactions of both Mb and Hb with nitro- and 
hydroxylamine-containing compounds. The reactions through both the oxidative and 
reductive pathways were predicted to result in heme-nitroso complexes, and although some 
did in fact result in heme-nitroso complexes in solution, a variety of other structural 
features resulted as well which was captured in their X-ray crystal structures, including Xe 
pocket adducts, S-nitrosation and hemichrome formation. 
It was shown that the interaction of ferric H64V swMbIII and nitrite results in an N-
bound ligand, matching that of the reported ferric H64V hhMbIII-nitrite structure. The 
interactions of wt and mutant ferric swMbIII-H2O with CAM and Mtz stressed the 
importance of H-bonding contributed by a distal residue, typically His64, to generate 
ferrous MbII-nitroso adducts. In the case of CAM, this required a more flexible Gln residue 
at position 64. Additionally, the reaction between ferric H64Q swMbIII-H2O and Mtz 
produced an O-bound acetamide derivative following the ring cleavage of Mtz.  
The X-ray crystal structure of the product of the reaction between AmphNHOH 
and ferric HbIII-H2O presented in this paper is the first to demonstrate the ability of Hb to 
accommodate bulky ligands in its active site. We have shown the importance of the 
movement of the E-helix in the  subunit of Hb, which creates the necessary space for 
AmphNO to bind at the Fe-center. Additionally, we have shown the presence of a ligand 
in the Hb  subunit Xe2 sites. Furthermore, the UV-vis spectroscopy results presented 
here, in combination with our previously published ferrous H64A MbII-AmphNO X-ray 
crystal structure43, provide strong evidence allowing us to infer what the three-dimensional 
structures of wt, H64Q and H64V MbII-AmphNO products would look like. Our data 
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shows that without a large distal residue such as His at the entry of the active site (e.g., in 
H64A Mb), no movement of the E-helix is necessary for AmphNO to enter the pocket and 
bind at the Fe-center. Our studies have shown that bulky ligands can in fact bind to the Fe-
center of both Hb and Mb, potentially inhibiting the binding of O2, leading to some disease 
states. This raises the question if our observations are limited to AmphNO or if other bulky 
ligands are also capable of binding at the Fe-center of Hb and/or Mb.  
The X-ray crystal structures of ferrous wt MbII-PhNO and [-FeIII(H2O)][-
FeIII(His)2-SNO]{PhNO} provide the first crystallographic evidence that the oxidation of 
PhNHOH to PhNO results in binding to Mb and induces large structural changes in Hb. In 
the case of Mb, PhNO binds to the Fe center, an interaction that likely inhibits the normal 
oxygen binding ability of Mb. Additionally, in the case of Hb, PhNHOH/PhNO caused the 
formation of a hemichrome in the  subunits, representing the earliest stages of Hb damage 
through heme loss. Formation of a hemichrome was also observed in the reaction of Hb 
with t-BuNHOH. The loss of hemes will likely lead to downstream disease states such as 
anemia. More importantly, the [-FeIII(H2O)][-Fe
III(His)2-SNO]{PhNO} and [-Fe
II][-
FeII-SNO]{CAMNO} structures showed that PhNO and CAMNO are capable of nitrosating 
the Cys93 of Hb, a result not previously anticipated. 
This large body of work presented in this chapter provides hard-to-obtain structural 
evidence for the wide range of products that can result from the reaction of Mb and Hb 
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Chapter 3. Clostridioides difficile nitroreductase 
 
3.1 Introduction 
Clostridioides difficile (formerly Clostridium difficile) is an anaerobic bacterium 
that colonizes the lower intestinal tract in humans and other mammals. C. difficile infection 
(CDI) caused by pathogenic strains can result in diarrhea, severe colitis or even death.1 
Reported cases of CDI in the United States alone exceeded 250,000 with 14,000 deaths in 
20132, with these numbers rising to ~500,000 with ~29,000 deaths in 2015.3 CDI 
occurrences are not only increasing in the US, but across the globe with many cases seen 
in Canada, Europe, Asia, India and many other areas of the world.4 Concerns about rising 
CDI have prompted the Centers for Disease Control (CDC) to label C. difficile as an urgent 
threat2 and for the White House to declare the reduction of CDI occurences a top priority.5  
One of the reasons for the increase in CDI occurrence is the frequent use of antibiotics 
which creates an imbalance in the intestinal microflora and allows C. difficile to thrive and 
colonize the gut.6 Another possible reason is the emergence of the NAP1/BI/027 family of 
C. difficile strains. As of 2009, this family accounted for ~61% of all clinical isolates.7 
R20291 is an epidemic and hypervirulent strain, part of the NAP1/B1/027 family, and was 
responsible for the Stokes Mandeville outbreaks in the United Kingdom in 2003 and 2004.8 
 
*Reproduced in part from, with permission, from “Crystal structures of two nitroreductases 
from hypervirulent Clostridium difficile and functionally related interactions with the 
antibiotic metronidazole” B. Wang*, S.M. Powell*, N. Hessami, F.Z. Najar, L.M. Thomas, 




Figure 3.1. Some of the more commonly prescribed drugs for CDI treatment. 
 
There are currently a variety of treatment options available for CDI (Figure 3.1). 
Metronidazole (Mtz) is a common and relatively low-cost nitro-containing drug prescribed 
for treatment  of  CDI.9, 10   Vancomycin,  a  glycopeptide,  is  also  commonly  prescribed  
for  CDI, however  it is more  often  prescribed for  severe and  recurring cases of CDI.12  
Fidaxomicin is a narrow-spectrum antibiotic designed specifically for the treatment of CDI 
and has shown similar levels of efficacy as vancomycin, but has not yet been widely 
accepted as a treatment option.13 Rifamixin is prescribed to complement vancomycin in 
cases of recurrent CDI.12 Apart from antibiotics, fecal microbiota transplant (FMT) has 
recently become more accepted as a treatment option for CDI, however there are many 
unanswered questions regarding how to properly choose a donor or how to properly 
administer FMT, preventing FMT from becoming a widely accepted first-line treatment 
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option.14 Despite the multitude of treatment options available for CDI treatment, Mtz 
remains the number one recommended treatment for CDI.15 
 Mtz typically functions as a prodrug and is metabolized by a class of nitroreductase 
(NR) enzymes to produce toxic metabolites that kill the pathogen. NRs are a family of 
FMN-dependent, NAD(P)H-linked proteins widely distributed in bacteria that typically 
exist as homodimers with protomers varying in size (23-30 kDa).16 Unlike myoglobin and 
hemoglobin which require the use of a metal, NRs function via either a two-electron (Type 
I) or one-electron (Type II) reduction pathway based on their response to oxygen (Figure 
3.2).  
 
Figure 3.2. Reduction pathways of nitro compounds by Type I (air-insensitive) and Type 
II (air-sensitive) NRs.16 
 
 A rising concern is the emergence of Mtz-resistant C. difficile strains. There are 
many reports that cite the failure of treatments for CDI with Mtz9, 17-20, however recent 
reports show an increased failure.21 A mutation resulting in a truncation of a NR was found 
in both a resistant strain and a sensitive strain of C. difficile with reduced susceptibility to 
Mtz, implicating NRs in Mtz resistance.22 Mtz resistance has been associated with NRs in 
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Bacterocides fragilis, the most-commonly found bacterium in clinical specimen,23-25 and 
Helicobacter pylori, the bacteria responsible for stomach ulcers.26, 27 
 Interestingly, although NRs are thought to be the primary enzymes responsible for 
Mtz metabolism in C. difficile, no NRs from the hypervirulent R20291 strain had been 
characterized prior to our work in this area. Further, only three NR crystal structures from 
the less-virulent C. difficile 630 strain had been deposited in the Protein Data Bank (PDB; 
with PDB id: 3GFA, 3EO8, and 3H4O/3KOQ), but no manuscripts describing these 
structures have been published. Importantly, in addition to lack of structural information 
of any NR from the hypervirulent C. difficile R20291 strain, no functional assays for the 
reaction of nitro substrates (e.g., Mtz) with NR from any C. difficile strain had been 
reported. 
 In this work, I determined one of the first two X-ray crystal structures of a NR 
(CDR20291_0767; NR_0767) from the hypervirulent C. difficile R20291 strain. I also 
investigated the reaction of nitro-containing compounds (see Mtz in Figure 3.1 and 
Figure 3.3) with this NR, and the results confirm the functional role of these proteins in 
the reductive metabolism of nitro-drugs by NRs in C. difficile. 
 
Figure 3.3. Structures of the nitro-containing compounds used in the NR redox-assay. 
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3.2 Material and Methods 
3.2.1 Cloning 
 A putative NR gene (CDR20291_0767) was identified from the annotated genome 
sequence of hypervirulent C. difficile and confirmed by a BLAST search28 against the 
conserved domain database.29 The recombinant plasmid pSGC-0767 containing the NR 
gene was constructed by our collaborators at Albert Einstein College of Medicine 
(AECOM). The plasmid also contained an N-terminal 6-His tag extension to facilitate its 
purification.  
 
3.2.2 Expression and purification 
 The plasmid pSGC-0767 was transformed into E. coli BL21 (DE3) competent cells. 
The NR (NR_0767) was expressed by autoinduction in ZY media supplemented with 
kanamycin (50 g/mL), MgSO4 (1 mM), glycerol (0.5% w/v), glucose (0.05% w/v), -
lactose (0.2% w/v), 100 M vitamin B12, and trace metals.
30 Autoinduction was performed 
at 37 C for 5 h and then adjusted to 22 C and left to incubate overnight. 
 Following centrifugation, the yellow cell pellets were harvested and transferred into 
a COY anaerobic chamber (3% H2 in nitrogen). All purification procedures were performed 
in the anaerobic chamber. The collected cells were resuspended in binding buffer (50 mM 
Tris, 500 mM NaCl, 5 mM -mercaptoethanol (ME), 20 mM imidazole, pH 8.0) that 
contained appropriate amounts of DNase, RNase and PMSF and then was sonicated on ice. 
After centrifugation, the supernatant was loaded onto a Ni-NTA affinity column (MCLAB) 
equilibrated with binding buffer. The column was then washed with wash buffer (binding 
buffer with 50 mM imidazole). The bound His-tagged protein was then eluted from the 
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column with elution buffer (binding buffer with 250-500 mM imidazole). Following Ni 
column elution, fractions containing the protein (as determined by SDS-PAGE) were 
combined. 
 The pooled protein was concentrated using an Amicon ultra filter with a cutoff of 
10 kDa (Millipore). The concentrated sample was applied to a gel filtration Superdex 200 
increase 10/300 GL column set up on an ÄKTA Pure system (GE Healthcare) inside a 
COY anaerobic chamber. The column was equilibrated with gel filtration buffer (50 mM 
Tris, pH 7, 150 mM NaCl, 1 mM EDTA and 2 mM -ME at pH 8.0). The elution profile 
of the protein was recorded by monitoring the absorption at 280 nm using the ÄKTA. The 
molecular mass of NR_0767 was estimated against the elution profiles of the standard 
proteins; conalbumin (75 kDa), ovalbumin (44 kDa), carbonic anhydrase (29 kDa), and 
ribonuclease A (13.7 kDa). Fractions containing the pure NR, as judged by SDS-PAGE, 
were pooled and concentrated to 10 mg/mL. The protein concentration was determined 
using a Bradford Standard Assay.  
 Purification procedures were also performed in open air for comparison.  
 
3.2.3 Redox assay of NR activity 
 Titration experiments for the reduction and re-oxidation of the FMN cofactors of 
NR_0767 were performed under anaerobic conditions as previously described.31 All 
buffers were purged with nitrogen gas for at least 30 min prior to being moved into the 
anaerobic chamber. A sealable quartz cuvette (Starna cells) with a septum was used. After 
each titration, the cuvette was sealed, and the absorption spectra read using a Hewlett 
Packard 8453 spectrophotometer. 
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For the reaction between NR_0767 and Mtz, ~18 M of NR in 3 mL of 50 mM Tris 
buffer at pH 8.0 was reduced by the addition of 7 sequential aliquots of 2 L of a stock 
solution of 12.5 mM dithionite in buffer in order to obtain the spectrum of the reduced 
form. Re-oxidation of the NR was performed by first reducing the protein followed by the 
addition of 8 sequential aliquots of 1 L of a stock solution of 20 mM Mtz in buffer. 
A similar procedure was followed for the reaction of NR_0767 with other nitro-
containing substrates: nitrobenzene (NB), CB-1954 and nitazoxanide (NTZ) (Figure 3.3). 
For the reaction of NR_0767 and NB, 1 L of 500 mM NB was added to reduced NR (~18 
M in 2.5 mL buffer). For the reaction with CB-1954, 1 L of 50 mM CB-1954 was added 
to reduced NR (~18 M in 2.5 mL buffer). And for the reaction with NTZ, 1 L of 50 mM 






Broad-screen crystallization trials for NR were carried out with a Mosquito robot 
(TTP Labtech) in the University of Oklahoma Macromolecular Crystallography 
Laboratory (MCL). The sitting drop vapor diffusion method was used by mixing 300 nL 
of protein (4-14 mg/mL) with 300 nL of well solution to form the drop. Each crystallization 
well contained 60 L of well solution. Crystallization was carried out in MRC 2 subwell 
plates (Swissci). 
Two peaks resulted from gel-filtration; one colorless (corresponding to a dimer) 
and one yellow (corresponding to a protomer). Fractions corresponding to these peaks were 
pooled separately and separate drops were set for each set of fractions. Only the yellow 
pooled fractions yielded crystals. These yellow rod-shaped crystals (~400 mm in length) 
formed after three days in well B3 (0.2 M diammonium hydrogen citrate, 20% PEG 3350) 
of an MCSG2 (Microlytic Inc.) broad screen. The crystals were briefly dipped in a 
cryosolution made of the crystallization well solution plus 15% glycerol, then immediately 
mounted on the goniometer for X-ray data collection. 
 
3.2.5 X-ray data collection, data processing, structure solution and refinement 
X-ray diffraction data of NR was collected at our home source in the MCL using a 
Rigaku MicroMax 007HF microfocus X-ray generator equipped with a Dectris Pilatus 200 
K silicon pixel detector. 
The data was collected at 100 K with Cu K radiation ( = 1.54178 Å) from the 
generator operated at the working condition 40kV/30 mA. The data were processed using 
HKL3000.32 The structure factors were calculated using the CCP4 program suite.33 The 
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three-dimensional structure of the full-length NR was solved by molecular replacement in 
PHASER (PHENIX) using a NR from Parabacteroides distasonis (PDB id: 3M5K) as a 
model.34 All refinements were performed by phenix.refine. The model was rebuilt using 
COOT.35 The MolProbity server was used for structure validation.36 
The initial 10 cycles of restrained refinement were run with phenix.refine, and the 
R factor decreased from 0.29 to 0.25. Ligands and water were added to the model according 
to the Fo-Fc electron density maps in the subsequent refinement cycles. Two FMN 
cofactors and two imidazoles (based on the electron density map, and the fact that 
imidazole was in the Ni column elution buffer) were introduced into the model using 
phenix.ligandfit. A total of 311 water molecules were sequentially added using COOT. The 
first 7 N-terminal residues of both protomer 1 and 2 were omitted because of the lack of 
electron density. The final R factor and Rfree are 0.18 and 0.23, respectively. The atomic 





3.3.1 Protein characterization 
The nitroreductase (CDR20291_0767; NR_0767) was expressed in high yield (~50 
mg/L) in E. coli. The protein was obtained in high purity (>90%) as shown by SDS-PAGE. 
The protein band seen on the gel was just below the 25 kDa marker matching the calculated 
NR mass of 23 kDa (Figure 3.4A). The gel filtration profile displayed two peaks (Figure 
3.4B). The first peak corresponds to the dimer, but the fractions were colorless due to the 
absence of the FMN cofactor. The second peak was yellow and corresponded to a 
monomer. The two sets were pooled separately for crystallization. Interestingly, the 
monomeric form that was present in solution resulted in a dimeric form after 
crystallization. Additionally, the dimeric form present in solution did not yield any crystal 
growth. 
 
Figure 3.4. Purification of NR_0767 was performed in two steps – a Ni-NTA column 
followed by gel filtration. (A) The SDS-PAGE gel after the Ni column. (B) Gel filtration 
chromatograph and SDS-PAGE. The colorless fractions pooled for crystallography are 











Initially, NR was purified anaerobically due to the anaerobic nature of C. difficile, 
but we determined that this protein can also be purified aerobically. Minimal differences 
were seen between the anaerobic and aerobic purifications (Figure 3.5). Crystallization of 
the protein was therefore carried out aerobically.  
 
 
Figure 3.5. Size exclusion chromatograph of NR_0767 comparing outcomes of (A) 
aerobic and (B) anaerobic purification. 
 
3.3.2 Reduction of nitro-drugs by NR 
The NR was reduced anaerobically using dithionite, with a corresponding color 
change from yellow (oxidized FMN, left in Figure 3.6) to colorless (reduced FMN, right 
in Figure 3.6). Oxidized NR has a typical absorption spectrum of a flavoprotein with 




Figure 3.6. Oxidation state of the NR co-factor, flavin mononucleotide (FMN). 
 
Upon dithionite addition, these peaks decreased in intensity (Figure 3.7). Reduced 
NRs are susceptible to reaction with oxygen, and even small amounts of air leaking into 
the cuvette will cause changes in the spectra due to re-oxidation of the reduced FMN. 
 
 
Figure 3.7. Reduction of NR showing absorbance changes of the oxidized FMN cofactor 
upon addition of dithionite. Conditions: 50 mM Tris buffer, pH 8, [NR] = 18 µM, each 




The reduced NR (in the absence of excess dithionite) was anaerobically re-oxidized 
by the addition of the nitro-containing drug (Figure 3.8), with a corresponding color 
change from colorless (reduced FMN) back to yellow (oxidized FMN). The absorbance at 
450 nm increased as the reduced protein (lowest dashed line) became oxidized (top thick 
line).  
 
Figure 3.8. Re-oxidation of NR by Mtz, showing the increase in intensity of the peak due 
to oxidized NR. Conditions: 50 mM Tris buffer, pH 8, [NR] = 18 µM, each addition is 1 
µL of 20 mM Mtz. 
 
 The same redox assay was performed using three other nitro-containing compounds 
to further establish the nitroreduction capability of this protein (Figure 3.9). NB is a simple 
nitro-containing compound, CB-1954 is an anticancer drug, and NTZ is an antiviral drug. 
In all three cases, after the addition of the nitro-substrate, a return of the peak at 450 nm 
was observed. These results show that NR_0767’s ability to reduce nitro-containing 






Figure 3.9. Re-oxidation of NR_0767 by NB (A), CB-1954 (B) and NTZ (C) showing 
the increase in intensity of the peak due to oxidized NR. Conditions: 50 mM Tris buffer 
pH 8, [NR] = 18 µM; reduced spectrum is after addition of 2 µL of 12.5 mM dithionite; 
oxidized spectrum is after addition of 2 µL of 500 mM NB (A), 1 µL of 50 mM CB-1954 
(B), and 1 µL of 50 mM NTZ (C). 
 
Having purified this NR from the hypervirulent C. difficile strain and having 
established its NR activity, we then proceeded to crystallize and determine its three-




3.3.3 Overall structure of NR from hypervirulent C. difficile R20291 
 After three days, yellow rod-shaped crystals (~450 mm in length) formed in well 
B3 (0.2 M diammonium hydrogen citrate, 20% PEG 3350) of an MCSG2 (Microlytic Inc.) 
broad screen. Figure 3.10 shows the crystal used for data collection. 
 
 
Figure 3.10. Crystal of NR_0767 used for X-ray data collection.  
 
 The structure of NR was solved to 2.1 Å resolution and represents one of the first 
two NR crystal structures from the hypervirulent C. difficile R20291 strain. The second 
structure, NR_0684, was obtained by my lab colleague Dr. Bing Wang. Data collection 
and refinement statistics are shown in Table 3-1. Including the N-terminal 6-His tag and 
the 16 extra linker residues, the cloned NR has a total of 201 amino acids per protomer. As 
mentioned in the experimental section 3.2.5, the first seven N-terminal residues of both 





Table 3-1. Data Collection and refinement statistics 
 NR_0767 
PDB ID 5J6C 
Data collectiona MicroMax 007HF 
Space group P21212 
Wavelength (Å) 1.54 
          Cell dimensions (Å) 67.91, 70.73, 87.88 
Resolution (Å) 50.00 – 2.10 
I/σ[I] 12.64 (2.18) 
No. of reflections  
    Observed 86479 
    Unique 25340 (1260) 
Multiplicity 3.4 (3.1) 
Completeness (%) 99.3 (99.4) 
Rmergeb 0.109 (0.454) 
CC1/2 0.814 
Refinement statistics  
No. of protein atoms 2898 
R factorc 0.18 
Rfreed  0.23 
RMSD Bond length (Å) 0.007 
RMSD Bond angles (°) 0.906 
Overall Mean B Factor (Å3) 25.42 
Ramachandran plot (%)e  
    most favored residues 98.3 
    outliers 0.00 
(a) Values in parentheses correspond to the highest resolution shells. (b) Rmerge = Σ|I-<I>|/Σ(I), where I is the individual 
intensity observation and <I> is the mean of all measurements of I. (c) R = Σ||Fo|-|Fc||/Σ|Fo|, where Fo and Fc are the 
observed and calculated structural factors, respectively. (d) Rfree was calculated by using 5% of the randomly selected 




 The crystal structure revealed that the NR is a homodimer (Figure 3.11) with each 
protomer binding one equivalent of FMN. The NR adopts the classic NR + fold31, 38 
within each protomer, with the FMN cofactors located near the interface of the protomers.  
 
Figure 3.11. Overall structure of NR _0767. Protomer 1 is drawn in purple, protomer 2 is 
drawn in cyan, FMN in orange and imidazole in red. 
 
Each protomer consists of a -sheet in the central core surrounded by -helices 
(Figure 3.12). The five-strand  sheet (51243) arrangement is formed from four 





Figure 3.12. PDBsum display of the secondary structure of a single monomer of NR.39 
 
A blastp search was used to identify homologs of NR_0767 using its amino acid 
sequence.40 Twelve total homologs were found across B. fragilis, G. metallireducens, D. 
hafniense, G. sulfurreducens, V. harveyi, B. subtilis, P. distasonis, M. smegmatis and P. 
gingivalis. The resulting potential homologs all showed <30% sequence identity when 
compared to NRs from the hypervirulent C. difficile strain R20291. Similar results were 
also obtained from 3D structural comparisons employing the Dali server.41 The potential 
homologs are annotated as either NRs or NAD(P)H:FMN oxidoreductases. Most of the 
homologs have a very similar overall protein fold (avg. RMSD 1.5-2.8 Å and Z score 21-




3.3.4 FMN and substrate binding sites 
 Each protomer contains an FMN cofactor located near the dimer interface (Figure 
3.11). The FMN binding site is accessible to solvent and several water molecules are 
involved in the interactions with the FMN cofactors and the residues above and below the 
FMN. The FMN binding site in protomer 1 (Figure 3.13A) is stabilized primarily by 
residues from this protomer, with interactions from only one residue (S43) of protomer 2. 
The other FMN (Figure 3.13B) is stabilized primarily by residues from protomer 2, with 
interactions from three residues (S42, S43, and K44) of protomer 1. Each of the FMN sites 
accommodates an imidazole molecule (present in the purification buffers) above the 
isoalloxazine group through a - stacking interaction (centroid to centroid distance of 3.8-
3.9 Å from the imidazole ring to the isoalloxazine group). In protomer 1, S43 interacts with 
the imidazole through a water network, but in protomer 2, S43 is directly involved in a H-
bond between O(S43) and N3(imid). The observed interaction between S43 and imidazole 
implies a likely role for S43 in substrate stabilization. 
 
Figure 3.13. FMN binding sites of NR_0767, including the imidazoles in red. Protomer 1 
(A) is drawn in purple, protomer 2 (B) is drawn in cyan, and FMN in orange. The 





3.4.1 Type I vs. type II NR 
The ability to aerobically purify NR_0767 allowed us to initially hypothesize that 
this NR functions as a Type I (oxygen insensitive) NR. The UV-vis spectral results of 
reduction and re-oxidation of the NR (Figure 3.7, Figure 3.8, Figure 3.9) display no 
absorbance at 600 nm that would have been indicative of a semiquinone state (middle of 
Figure 3.6) generated by one-electron reduction of the FMN cofactor.37 This further 
supports our hypothesis that this NR functions as a Type I NR and follows a two-electron 
reduction pathway with nitro-containing species. 
We are currently unsure of the identity of the primary organic product(s) resulting 
from the nitro-containing drug reduction by this C. difficile NR. Based on literature 
precedent,42 we speculate that the nitro-drug is reduced to an initial nitroso derivative that 
readily converts under our experimental conditions to the bioactive hydroxylamine 
product. We are pursuing the isolation and identification of the primary and secondary 
products following the methods of Çelik, et al.43, however our efforts using both GC-MS 





3.4.2 Comparison of overall NR fold 
The crystal structure of a second NR from C. difficile R20291 (CDR20291_0684; 
NR_0684) has also been solved in our lab by Dr. Bing Wang. Using a blastp search, 
NR_0767 and NR_0684 have 24% sequence identity over 186 amino acids.40 Despite the 
low sequence identity, the overall folds of the two proteins are quite similar (Figure 3.14). 
The RMSD is 2.3 Å for protomer 1, and 2.9 Å for protomer 2. The core of the protomers 
and the dimer interface overlay quite well. The largest difference between the two 
structures is a result of the unique segment in NR_0684, which does not align with 
NR_0767 in either protomer 1 or 2. We are currently unsure of the importance of this 
unique structural feature. 
 
Figure 3.14. Overlay of the X-ray crystal structures of NR_0684 (green) and NR_0767 
(this work, purple). 
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3.4.3 Potential substrate binding site 
Our NR_0767 structure shows a loop area (between 2 and 1) above the 
isoalloxazine ring of FMN; this loop area is also present in some other NRs.38, 42, 44 S43 of 
NR_0767 (underlined in Figure 3.13) is located in this loop. This loop appears to play an 
important role in the interaction and stabilization of the imidazole. A structural comparison 
between our NR and an E. coli NR complex with bound nitrofurazone (PDB id: 1YKI)42 
showed that the position of the imidazole in NR_0767 overlaps with the semicarbazone 
“tail” of nitrofurazone in the E. coli NR (Figure 3.15). The comparison suggests that the 
position of the imidazole in our NR is a potential substrate binding site for Mtz when it 
reacts with NRs, since Mtz also contains an imidazole ring. Thus, the loop between 2 and 
1 (residues 44-53) may play a significant role in accommodating substrates such as Mtz. 
 
Figure 3.15. Superposition of the FMN binding sites of NR_0767 from C. difficile 
R20291 and a NR (PDB accession code 1YKI) from E. coli. The FMN and imidazole 
from NR_0767 are represented in light green and green, respectively. The FMN and 




Sequence alignments (Figure 3.16) of the two C. difficile NRs shown above, with 
NRs from H. pylori and E. coli show that the two ends of this loop area are well conserved, 
leaving the center area of the loop variable. The variable region of this loop may help 
explain the differences in substrate binding specificity between NRs. 
We are currently pursuing a co-crystal structure of NR_0767 with a nitro-





Figure 3.16. Sequence alignment of NRs from three different strains. NR_0767 and 
NR_0684, from C. difficile R20291; RdxA and FrxA, two NRs from H. pylori; and NfsB, 
a NR from E. coli. Secondary structure was assigned according to our NR_0767 





3.4.4 Importance of Cys117 
 As mentioned in the introduction, Mtz resistance has been associated with NRs in 
H. pylori.26, 27 The primary NRs in H. pylori are RdxA and FrxA, however, only RdxA has 
been linked with H. pylori Mtz susceptibility.38 Like C. difficile NR_0767, RdxA forms a 
dimer and within each protomer, forms the classic NR + fold and the FMN cofactors are 
located near the interface of the protomers. The RMSD between NR_0767 and RdxA is 
3.211 Å (Figure 3.17) and their sequence identity is 32% (see Figure 3.16 for alignment). 
 
Figure 3.17. Overlay of the X-ray crystal structures of H. pylori RdxA (PDB id: 3QDL) 
and C. difficile NR_0767 (this work, cyan).  
 
 Martínez-Julvez, et al. reported the importance of Cys159 which is proximal to 
FMN in the active site.38 They found that mutations at this site drastically reduced Mtz 
reduction. It was predicted that due to its proximity (3.8 Å) to N1 of FMN, which can be 
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protonated once FMN is fully reduced (right of Figure 3.6), that Cys159 is involved in the 
protonation of FMN and thus directly involved in Mtz reduction. NR_0767 also possesses 
a Cys at this site (Cys117) which is at a similar distance from N1 (3.6 Å) as Cys159 in 
RdxA is (Figure 3.18). Mutagenesis studies need to be performed to confirm the 
importance of Cys117 in NR_0767, however, based on the structural comparisons with 
RdxA, it is likely that Cys117 plays a role in NR_0767 Mtz metabolism. 
 
 
Figure 3.18. Overlay of the FMN active site and proximal Cys of H. pylori RdxA (PDB 







In this chapter, I have reported the expression, purification and structural 
characterization of one of the first two C. difficile NRs from the hypervirulent R20291 
strain. Redox assays with Mtz, NB, NTZ and CB-1955 show that NR_0767 does indeed 
function as a nitroreductase and more specifically, a Type I nitroreductase. Based on 
structural comparisons, we have established the likely importance of the loop between 2 
and 1 (residues 44-53) in substrate specificity and Cys117 in Mtz reduction. Additionally, 
our group’s work with NR_0767 and NR_0684 was the first reported observation of the 
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Chapter 4. Cytochrome P450 BM3-HD 
 
4.1 Introduction 
Cytochromes P450 (P450s) belong to a very large superfamily within the even 
larger family of mono-oxygenases.1 The primary reaction of P450s is O-atom insertion into 
a C-H bond and this is accomplished with the help of a heme prosthetic group (Figure 4.1). 
In its ferric resting state, water binds to the axial (sixth) position (1 in Figure 4.1). Binding 
of a ligand to the pocket (away from the Fe) causes the water to be released, beginning the 
catalytic cycle which requires the entry of O2. 
 
Figure 4.1. Cytochrome P450 oxygenase mechanism.2 The intermediates are numbered. 
 
P450s perform a large variety of functions such as steroid production and fatty acid 
metabolism. However, they are best known for their role in drug metabolism as the vast 
majority of human P450s are located within the liver.2 P450s are responsible for ~74% of 
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all xenobiotic metabolism within the human body.2 All P450s contain a heme domain and 
a reductase partner that shuttles electrons from NAD(P)H to the heme center. The type of 
reductase/redox partner defines what class the P450s are within. There are ten total classes 
of P450 systems, however mammalian P450s all fall into class I or II.1 Class I P450s partner 
with a redoxin to shuttle electrons from a membrane-bound NAD(P)H-dependent reductase 
creating a three-protein system (Figure 4.2A), while class II P450s contain a membrane-
bound NADPH–cytochrome-P450 reductase (CPR), creating a two-protein system (Figure 
4.2B).3 Most human P450s are considered to be class II. 
 The difficulty in studying mammalian P450s is that they are membrane-bound and 
therefore difficult to solubilize. In 1981, a bacterial P450 system was discovered in Bacillus 
megaterium.4 This P450, termed BM3 (CYP102A1), conveniently possesses both the P450 
heme and reductase domains in a single polypeptide, and is classified as a class VIII P450 
(Figure 4.2C).1 Additionally, P450 BM3 is not membrane bound and is therefore much 
easier to solubilize. Not long after its discovery, it was reported that P450 BM3 functions 
like a Type II system and since that time, P450 BM3 has been used as a model system for 
human P450s.5  
 
Figure 4.2.  Classes of P450 systems. 
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Full-length P450 BM3 is a 119 kDa protein, but for the purposes of this study that 
focuses on ligand binding, only the P450 BM3 heme domain (BM3-HD) was used. The 
heme domain of BM3 is 55 kDa and corresponds to residues 1-455.4, 6 Unlike myoglobin 
(Mb) and hemoglobin (Hb), the proximal ligand to the heme in P450 BM3-HD is a cysteine 
rather than a histidine. The overall structure and active site of P450 BM3-HD in complex 
with palmitoleic acid are shown in Figure 4.3. An important structural feature is the I-helix 
which houses Thr268. The I-helix helps to make up the substrate binding region and 
Thr268 is an important residue in oxygen binding and activation, thus making it important 
for substrate binding as well.7 In addition to Thr 268, both Ala264 and Phe87 have been 
shown to contribute to the substrate specificity of P450 BM3-HD, while Arg47, Ala82 and 
Val78 have been shown to act as “gatekeepers” along the substrate entrance to the heme 
pocket.8, 9 Additionally, the active site volume of P450 BM3-HD (~500 Å3) is much larger 
than that of Mb (~50 Å3) and Hb (~50 Å3), allowing for a much greater diversity of 
substrates (based on size) that can bind within the active site. 
 
Figure 4.3. (A) Overall structure and (B) active site of BM3 heme domain with bound 
palmitoleic acid (PDB id: 1FAG). Palmitoleic acid is shown in magenta and the I-helix is 
shown in blue in (A). 
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UV-vis spectroscopy has historically been used as a powerful tool to study 
interactions of P450s with substrates, as the heme chromophore has characteristic 
absorptions for the various ferric and ferrous liganded states.10 In fact, P450s get their name 
from their characteristic absorbance band at 450 nm in the Soret region when the ferrous 
form is bound to CO.11, 12 Ligands can bind to either the amino acid residues in the heme 
active site (Type I) or can coordinate directly with the heme-Fe (Type II) as shown in 
Figure 4.4A. Type I difference spectra have a characteristic maximum at 390 nm and 
minimum at 420 nm, while Type II difference spectra display a characteristic minimum at 
415 nm or lower and a maximum between 425 and 440 nm in (Figure 4.4B).2 Many 
inhibitors of P450s bind in a Type II fashion, including N-containing compounds which 
bind through their N-atoms to the heme-Fe. In doing so, they block the binding of O2, 
halting the catalytic cycle (Step between intermediates 3 and 4 in Figure 4.1).8 In this 
chapter, I present a spectroscopic investigation of the reactions between P450 BM3-HD 
and three N-containing sets of ligands, namely C-nitroso compounds, imidazoles and 
hydrazines. 
 
Figure 4.4. (A) Ligands can bind to P450s in a Type I or Type II binding mode. (B) The 
difference spectra of Type I (solid line) have a max at ~390 nm and min of ~420 nm, 
while Type II (dashed line) have a min 415 nm or lower and min of 425-440 nm. 
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C-nitroso compounds (RNO, R = alkyl or aryl) are formed from the oxidative 
metabolism of their hydroxylamine precursors or from the reductive metabolism of their 
nitro precursors.13 It is known that these RNOs can inhibit P450s by binding at their Fe 
centers, preventing further binding of O2.
14-16 The inhibitory complexes that form are 
characterized by a ~455 nm peak in the Soret region. RNOs can cause an accumulation of 
prescription drugs in the liver during multi-drug treatments, as the first RNO-metabolite of 
one drug will bind to P450 forming a complex which further inhibits any reactions with a 
second drug.14 In 1976, Mansuy published a study describing the formation of heme-RNO 
complexes in rat liver microsomes when treated with nitroalkanes.17 However, there are no 
reported studies involving P450 BM3-HD and RNOs. Additionally, there are no crystal 
structures in the Protein Data Bank (PDB) of any P450-nitrosoalkane complexes. The RNO 
ligands used in this study are shown in Figure 4.5. 
 
Figure 4.5. RNO ligands used in this study. 
 
Imidazoles have a high affinity for heme proteins. Due to this, imidazole groups 
are a common moiety in P450-targetted drugs.18, 19 For example, ketoconazole is an 
imidazole-based inhibitor of P45017 (CYP17A) used in treatment of prostate cancer.
20 
Miconazole and clotrimazole are imidazole-based inhibitors of aromatase (CYP19A) used 
for breast cancer therapy.19 There are no published studies of P450 BM3-HD with simple 
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imidazoles. There are, however, many X-ray crystal structures of other P450s with 
imidazoles, but there is only one structure of P450 BM3-HD in complex with any simple 
imidazole (PDB id: 4KF2) and it is a double mutant of P450 BM3-HD.9 The imidazoles 
used in my work are shown in Figure 4.6. 
 
Figure 4.6. Imidazole-based ligands used in this study. 
 
Hydrazines are of interest due to their ability to cause adverse health effects in 
humans such as cancer, liver damage, hemolytic anemia and reticulocytosis.21, 22 They are 
components of isoniazid, an antibiotic prescribed for tuberculosis, and of hydralazine, a 
medication used to treat high blood pressure and heart failure. Additionally, hydrazines are 
environmental toxins and are used in rocket fuels, plastic foams and farming chemicals. 
Hydrazines are toxic to humans both through inhalation and ingestion. In Mb and Hb, 
reaction with hydrazines causes damage to the protein and in the case of Hb, can lead to 
formation of Heinz bodies.23 However, due to the larger site of the P450 active site, P450s 
can interact with hydrazines without damage occurring in the protein, but they can still 
inhibit the activity of these proteins.24 There is currently only one crystal structure of the 
product formed between any P450 and a hydrazine, namely of P450cam in complex with 
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a phenyl group after reaction with phenyldiazene (PDB id: 1CP4).25 There is also only one 
reported study of P450 BM3-HD with hydrazines.26 The focus of this study will be the 
arylhydrazines (ArNHNH2, Ar = aryl) shown in Figure 4.7. 
 
Figure 4.7. Arylhydrazine ligands used in this study.  
 
The goal of this chapter is to fill the gaps in knowledge surrounding the interactions 
of P450 BM3-HD with C-nitroso compounds, imidazoles and hydrazines. This work was 
performed primarily using UV-vis spectroscopy to probe these interactions.  
 
167 
4.2 Materials and Methods 
 
4.2.1 Cloning and Expression of P450 BM3 Heme Domain (P450 BM3-HD) 
Plasmids containing only the heme domain of P450 BM3 (BM3-HD) were a 
generous gift from Dr. Thomas Poulos from University of California at Irvine. These 
plasmids were transformed into either E. coli DH5 or BL21 (DE3) cells and subsequently 
expressed in LB media. 
Expression trials were performed to optimize the expression of P450 BM3-HD 
based on literature precedent.27-30 Expression was carried out at varying temperatures (28 
– 37 C) for varying times (15 – 48 h). The amount of ampicillin in the starting LB (100 or 
120 g/mL) and the amount of IPTG to add (0.5 mM or 1 mM) to induce expression was 
varied. The point at which to add isopropyl  -D-1-thiogalactopyranoside (IPTG) also 
varied (OD600 = 0.5 – 1.0). I also tested the addition of more ampicillin at the time when 
IPTG was added. Additionally, attempts were made to increase the heme content of the 
expressed protein by adding aminolevulinic acid (ALA), the heme precursor, to the growth 
media. Ultimately, it was found that the best conditions for expression of P450 BM3-HD 
was to use LB supplemented with 120 g/mL ampicillin and to grow the cells until OD600 
reached 0.6 – 0.7, at which point 0.5 mM IPTG and 120 g/mL ampicillin were added. The 
temperature was adjusted to 30 C and cells were left to grow for 15-18 h before being 




4.2.2 Purification of P450 BM3-HD 
Frozen cell pellets were thawed and resuspended in Buffer A (30 mM potassium 
phosphate pH 7.4, 0.1 mM EDTA, 10 mM ME). The cells were lysed using an Emulsiflex. 
Following lysis, multiple methods of purification were tested27-30 to yield high purity P450 
BM3-HD. The efforts are summarized below. 
The first purification attempts included an initial streptomycin sulfate precipitation 
step and dialysis prior to any chromatography, but these steps were later found to be 
unnecessary as they did not improve yield or purity. Different combinations of DEAE 
anion exchange, Q-sepharose anion exchange and S-200 gel filtration columns were used 
to achieve high purity. The column chromatography was performed in the University of 
Oklahoma Protein Production Core (PPC) on a GE ÄKTA FPLC. Following each 
chromatography step, SDS-PAGE gels were run to evaluate purity and to select which 
fractions to pool for the subsequent step. In addition to SDS-PAGE gels, the ÄKTA was 
equipped with a second UV-vis detector set to 420 nm which assisted in the selection of 
fractions containing the target protein. The final pure protein was concentrated to ~25 
mg/mL using its extinction coefficient at 418 nm (95 mM-1cm-1).31 
To increase heme content, heme reconstitution was performed following 
purification.32, 33 Dithiothreitol (DTT; 20 mM) was added to concentrated P450 BM3-HD, 
and dissolved hemin (2.5 mg in minimal 0.1 M KOH diluted with ddH2O to 1.5 mL) was 
added dropwise and left to stir at room temperature for ~24 h. The sample was centrifuged 
to remove any excess hemin and the pellet was discarded. The supernatant contained the 
final ferric P450 BM3-HD used for all further experiments. 
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4.2.3 UV-vis studies of P450 BM3-HD with N-containing ligands 
UV-vis spectroscopy, using a Hewlett Packard 8453 spectrophotometer, was used 
to monitor the aerobic reactions of P450 BM3-HD with the three different sets of N-
containing ligands. 
 
4.2.3.1 C-nitroso compounds 
The interactions of ferric P450 BM3-HD with C-nitroso compounds (RNO where 
R = alkyl or aryl, Figure 4.5; nitrosomethane (MeNO), nitrosoethane (EtNO), 1-
nitrosopropane (PrNO), 2-nitrosopropane (i-PrNO), and nitrosobenzene (PhNO)) were 
studied following the methods of a former lab member, Dr. Daniel Copeland.34 Reduction 
of the Fe-center of ferric P450 BM3-HD followed by reaction with the nitro-precursors 
(RNO2; R = alkyl or aryl), yields their respective nitroso products (RNOs). Initially, 2.4 
mL of buffer (100 mM sodium phosphate, pH 7.4) and 25 L ferric P450 BM3-HD (25 
mg/mL) were mixed in a quartz cuvette (Starna cells). 50 L sodium dithionite (1 M) was 
added and immediately followed by the addition of 25 L nitro-substrate (1 M; ~2000x 
excess). Reaction time of zero was set at the addition of nitro-substrate. 
 
4.2.3.2 Imidazoles 
Ferric P450 BM3-HD and its interaction with the imidazoles (Figure 4.6; imidazole 
(Im), 1-methylimidazole (1-MeIm), 2-methylimidazole (2-MeIm), 4-methylimidazole (4-
MeIm), 1,2-dimethylimidazole (1,2-diMeIm), 1-ethylimidazole (1-EtIm), 2-
ethylimidazole (2-EtIm), and 2-ethyl-4-methylimidazole (2-Et-4-MeIm)) were studied. 2.5 
mL of buffer (100 mM sodium phosphate, pH 7.4) and 20 L ferric P450 BM3-HD (25 
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mg/mL) were mixed in a quartz cuvette (Starna cells) for an initial spectral reading. 10 L 




Ferric P450 BM3-HD and its interaction with arylhydrazines (Ar-NHNH2, Ar = 
aryl; Figure 4.7; phenylhydrazine (PhHZ), 3-methylphenylhydrazine (3-MePhHZ), and 4-
chlorophenylhydrazine (4-ClPhHZ)) were studied. 2.5 mL of buffer (100 mM sodium 
phosphate, pH 7.4) and 20 L ferric P450 BM3-HD (25 mg/mL) were mixed in a quartz 
cuvette (Starna cells) for an initial spectral reading. Time zero was set at the addition of 2 
L hydrazine-substrate (0.5 M, ~100x excess) to the cuvette. Readings were taken at 
different time points during the reaction to monitor formation of products. 
 
4.2.4 Crystallization Attempts 
 Efforts were made to obtain a crystal of ferric P450 BM3-HD using a variety of 
crystallization conditions. Initial efforts followed the methods of Li, et. al (0.05 M HEPES 
pH 7.0, 2.0-3.0 M ammonium sulfate, 2-6% MPD).27 Conditions were also optimized 
around published conditions from crystal structures in the PDB – 3BEN (11% PEG 3350, 
200 mM MgCl2, 7.5% glycerol, 100 mM MES pH 6.0), 2J1M/2J4S (0.04-0.05 M Zn 
acetate, 15-20% PEG 3350, 14% DMSO) and 2IJ2 (100 mM cacodylate pH 6.0, 160 mM 
MgCl2, 18% PEG 3350). A number of broad screens were also tested – MCSG1-4, Wizard, 
CSHT, MIDAS and Morpheus. Finally, I attempted co-crystallization with MeNO, EtNO, 





4.3.1 Expression and purification of P450 BM3-HD 
 P450 BM3-HD was successfully overexpressed in E. coli BL21 cells (Figure 4.8). 
The sample taken following induction (I) has a much thicker band at ~50 kDa than the 
sample taken prior to induction (uninduced; U). The position of this band matches the 
calculated molecular weight of P450 BM3-HD of 53.2 kDa. 
 
Figure 4.8. SDS-PAGE gel of P450 BM3-HD following induction with IPTG. The 
induced (I) lane shows the overexpression of P450 BM3-HD (52.3 kDa) compared to the 
uninduced (U) sample. 
 
After optimizing the expression conditions, I moved on to optimizing the 
purification strategy. Initial attempts included a streptomycin sulfate precipitation followed 
by dialysis to remove any excess streptomycin sulfate, and separation using a Q-sepharose 
anion exchange column and finally an S-200 gel filtration column.27 As is shown in Figure 
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4.9, the purity of the protein was very poor following the final purification step. Additional 
efforts were made to increase protein purity. 
 
Figure 4.9. P450 BM3-HD purification chromatographs of the (A) Q-column and (B) S-
200 gel filtration. Red bars along the x-axis of the chromatographs indicate where 
fractions were pulled from. Below each chromatograph is its corresponding SDS-PAGE. 
 
Following the methods of Di Nardo, et. al,30 the streptomycin sulfate step was 
eliminated and the use of a DEAE column was added. The final purification strategy 
consisted of separation using a DEAE anion exchange column, buffer exchange to remove 
salt, a Q-sepharose anion exchange column and finally an S-200 gel filtration column. As 






Figure 4.10. P450 BM3-HD purification chromatographs of the (A) DEAE column, (B) 
Q-column, and (C) S-200 gel filtration. Red bars along the x-axis of the chromatographs 




4.3.2 Reactivity with C-nitroso compounds 
 UV-vis spectroscopy was used to monitor the reactions of ferric P450 BM3-HD 
with MeNO, EtNO, PrNO, i-PrNO, and PhNO. In all cases, an initial spectral reading of 
ferric P450 BM3-HD was taken and a peak at 419 nm in the Soret band was observed 
which verified the presence of the oxidized ferric form. After the simultaneous addition of 
sodium dithionite and the RNO2 precursor, a decrease at 419 nm and the appearance of a 
new peak at 452 nm was observed (Figure 4.11). The appearance of a peak at 452 nm 
indicates the reduction of both the heme and the RNO2 to its respective ferrous Fe
II-RNO 
form, specifically, the formation of an N-bound FeII-RNO derivative. PhNO was also 
tested; however, no differences were observed in the spectra even after 60 min of reaction. 
 
Figure 4.11. UV-vis spectroscopy of ferric P450 BM3-HD (solid line) in reaction with 
RNO2 precursors, resulting in ferrous P450 BM3-HD-RNO complexes. The result at 60 
min is shown as a dashed line. (A) MeNO, (B) EtNO, (C) PrNO, (D) i-PrNO. Conditions: 
100 mM sodium phosphate buffer pH 7.4, [P450 BM3 HD] = 4.8 M, [dithionite] = 20 
mM, [substrate] = 10 mM  
 
175 
4.3.3 Reactivity with imidazoles 
UV-vis spectroscopy was used to monitor the reactions of ferric P450 BM3-HD 
with Im, 1-MeIm, 2-MeIm, 4-MeIm, 1,2-diMeIm, 1-EtIm, 2-EtIm, and 2-Et-4-MeIm. The 
UV-vis spectrum of P450 BM3-HD with Im is shown in Figure 4.12A. Upon addition of 
Im, a shift in the Soret band from 418 nm to 421 nm was observed. Similar shifts were seen 
for the reaction of ferric P450 BM3-HD with 1-MeIm, 4-MeIm, and 1-EtIm. No reactions 
were observed for all the 2-substituted imidazoles presumably due to the steric clashes 
between the imidazole-substituents and the porphyrins rings.35 
 
Figure 4.12. UV-vis spectrum of ferric P450 BM3-HD with Im (A), as well as the 
calculated difference spectrum (B). Conditions: 100 mM sodium phosphate buffer pH 
7.4, [P450 BM3 HD] = 3.8 M, [substrate] = 4 mM 
 
 To determine the type of binding between the imidazoles and ferric P450 BM3-
HD, a difference spectrum was calculated. As shown in Figure 4.12B, for Im, a max was 
observed at 434 nm and min was observed at 413 nm. These peaks are indicative of Type 
II binding. Similar peaks were observed in the difference spectra for 1-MeIm, 4-MeIm, and 
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1-EtIm as shown in Table 4-1. These results are consistent with literature that imidazoles 
should bind P450s in the Type II binding mode.36 
 
Table 4-1. Difference spectra peaks for P450 BM3-HD with imidazoles. 
 Im 1-MeIm 4-MeIm 1-EtIm 
λmin 413 413 414 413 





4.3.4 Reactivity with arylhydrazines 
 UV-vis spectroscopy was used to monitor the reactions of ferric P450 BM3-HD 
with PhHZ, 3-MePhHZ and 4-ClPhHZ. The UV-vis spectrum of P450 BM3-HD in reaction 
with PhHZ is shown in Figure 4.13. Immediately after the addition of PhHZ, a shift is seen 
in the Soret band from 418 nm to 421 nm (Figure 4.13A). Similar to that seen with the 
imidazoles, after a difference spectrum was calculated, a max at 434 nm and min at 413 
nm was observed. This pattern in the difference spectrum indicates Type II binding. Unlike 
the imidazoles, however, the reactions do not stop after this first step. Over time, a 
disappearance of the peak at 421 nm, and an appearance of a peak at 480 nm was evident 
(Figure 4.13B). Similar shifts were seen for both 3-MePhHZ and 4-ClPhHZ. 
 
 
Figure 4.13. UV-vis spectrum of ferric P450 BM3-HD with PhHZ. (A) The spectrum 
after the initial addition of PhHZ and (B) the changes in the spectrum over time. 
Conditions: 100 mM sodium phosphate buffer pH 7.4, [P450 BM3 HD] = 3.8 M, 




 The time that it took for the peak at 421 nm to begin decreasing varied between 
ligands (Figure 4.14). For PhHZ, the shift toward 480 nm began at ~40 min (Figure 4.14A) 
and the reaction reached its peak at ~150 min. After ~150 min however, the absorbance at 
480 nm began to decrease, indicating instability of the product. For 3-MePhHZ, the shift 
toward 480 nm began at ~30 min and the reaction reached its peak at ~180 min (Figure 
4.14B). The product appeared to be stable as there was very little decrease in the 
absorbance at 480 nm up to ~300 min. For 4-ClPhHZ, the shift toward 480 nm began at 
~10 min and the reaction reached its peak at ~80 min (Figure 4.14C). This product 




Figure 4.14. Time course of the reactions of ferric P450 BM3-HD with (A) PhHZ, (B) 3-




 Crystallization efforts of the ferric P450 BM3-HD protein have not yet, in my 
hands, yielded crystals. Figure 4.15 shows the resulting hanging drops of four of the many 
conditions attempted. The lack of crystal formation is likely due to insufficient purity of 




Figure 4.15. Various crystallization conditions resulting in P450 BM3-HD precipitation, 







4.4.1 Relationship of C-nitroso ligand sterics and extent of complex formation 
As can be seen in Figure 4.11, the RNOs reacted with ferric P450 BM3-HD to 
varying degrees. To determine the difference in RNO reactivity with ferric P450 BM3-HD, 
the extent of formation was calculated based on the disappearance of the peak at 419 nm. 
It was calculated as the change in absorbance at 419 nm divided by the initial absorbance 
at 419 nm and multiplied by 100 (419/419). The results are displayed in Figure 4.16. 
 
 
Figure 4.16. Extent of formation for the reactions of ferric P450 BM3-HD with RNOs 
from (A) this work and (B) related work by Dan Copeland.34 
 
 Over a one-hour period, the extent of formation with MeNO was 11%, EtNO was 
24%, PrNO was 11% and i-PrNO was 48%. Since I was following the methods of Dan 
Copeland, my results (Figure 4.16A) were compared with his  (Figure 4.16B). Copeland’s 
results for extent of formation at the one-hour time point were similar to my work (MeNO 
was 16%, EtNO was 36%, PrNO was 19% and i-PrNO was 60%). His values were 
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consistently higher than mine, which could be attributed to minor differences in starting 
conditions such as initial protein concentration.  
As the alkyl group increases in size from methyl → ethyl → isopropyl, the extent 
of formation with ferric P450 BM3-HD increases as well. The exception to this steric trend 
is PrNO, which reached a maximum extent of formation matching that of MeNO. The same 
trend was observed in Copeland’s work. This exception to this trend can be explained by 
an examination of the P450 BM3-HD active site and by computationally “docking” the 
respective RNO ligand as N-bound to the Fe-center in the previously determined X-ray 
structure of this protein. The predicted structures of the ferrous P450 BM3-HD-RNO 
complexes were constructed in Pymol and are displayed in Figure 4.17. The orientations 
of the artificially placed RNOs were fixed, guided by other reported hemoprotein-RNO 
crystal structures.37 MeNO, EtNO and i-PrNO, were readily modeled in the active site as 
N-bound ligands, with the alkyl groups oriented towards the hydrophobic interior of pocket 
leaving the O-atom of each RNO ligand to H-bond with the nearby Thr268 (Figure 4.17A, 
B, D). For PrNO, the terminal methyl group clashes with both Phe87 and Ala264 (Figure 
4.17C; closer than the sum of Van der Waals radii38), making it difficult for the n-propyl 
chain to find a stable position in the active site. I note that Phe87 has been shown to 
influence substrate specificity in P450 BM3-HD8, 9 and this could explain why the extent 




Figure 4.17. Predicted ferrous P450 BM3-HD-RNO interactions modeled into the P450 
BM3-HD active site using the protein structure from PDB id: 1FAG. (A) MeNO, (B) 
EtNO, (C) PrNO, (D) i-PrNO. 
 
 The trends observed for the extent of formation for the ferrous P450 BM3-HD-
RNO derivatives are also comparable to the work performed by Mansuy with rat liver 
microsomal P450’s (Figure 4.18).17 In my work, following the methods of Copeland, I 
calculated the extent of formation based on the disappearance of the starting material peak 
at 419 nm. This was attributed to the fact that calculating the extent of formation based on 
the appearance of the product peak at 452 nm would likely result in an inaccurate 
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comparison since each of the four ligand complexes would have a different extinction 
coefficient. However, in Mansuy’s work, he calculated the extent of formation using the 
difference between the product peak at 455 nm and an isosbestic point at 490 nm (Abs 
455-490 nm) as shown in Figure 4.18B. In order to compare my results to Mansuy’s, I 
recalculated the extent of formations using a similar method (Figure 4.18A). While minor 
differences exist, the overall trends observed in Figure 4.16A still hold up after using a 
different method to calculate the extent of formation. 
Three ligands overlap between Mansuy’s work and my work; MeNO, EtNO, and i-
PrNO.  The extent of formation trend for Mansuy’s work is EtNO > i-PrNO > MeNO. This 
trend is somewhat similar to that presented in this work (i-PrNO > EtNO > MeNO), but 
with a difference in the relative position of i-PrNO. Unlike P450 BM3-HD, which has a 
bulky Phe at position 87 (Figure 4.17), the equivalent residue in microsomal P450s is 
typically a much less bulky residue such as Gly.8 By replacing Phe with Gly, this weakens 
the hydrophobic interactions between i-PrNO and the active site pocket, causing i-PrNO to 
be less stable in the pocket of microsomal P450s and thus lower its extent of formation. 
The fact that the trends are somewhat similar between P450 BM3-HD and microsomal 





Figure 4.18. Comparison of appearance of the product peak for (A) P450 BM3-HD and 
(B) Mansuy’s work with rat liver microsomes in reaction with nitro-compounds.17 
 
 It should also be noted that there was no reaction between ferric P450 BM3-HD 
and nitrobenzene (PhNO2) under our conditions. P450-PhNO complexes have been 
reported previously, however, the complexes were formed through the reaction of PhNO 






4.4.2 P450 BM3-HD-imidazole complexes 
 Imidazoles, more specifically 1- and 4-substituted imidazoles, have long been 
known to be inhibitors of P450s. The first reported study of the interactions of 
alkylimidazoles with microsomal P450s was published in 1974.41 Prior to my current work, 
there were no reports describing the interactions of ferric P450 BM3-HD with 
alkylimidazoles using UV-vis spectroscopy.  
In my work, ferric P450 BM3-HD was reacted with Im, 1-MeIm, 2-MeIm, 4-MeIm, 
1,2-diMeIm, 1-EtIm, 2-EtIm, and 2-Et-4-MeIm. Curiously, no reaction occurred upon 
addition of 2-substituted imidazoles under our reaction conditions. Rogerson, et al. 
reported that sterics play a large part in the interaction of imidazoles with P450s, therefore 
2-substituted imidazoles are likely to have reduced or no reactions with P450s.35 With the 
1- and 4-substituted imidazoles, shifts in the Soret max from 418 to 421 nm were observed 
for the complexes (Figure 4.12A), matching literature values for imidazole-based fatty 
acids in their interactions with ferric P450 BM3-HD.8  
The difference UV-vis spectra were also calculated for each successful reaction 
(Figure 4.12B). The max and min were consistently observed at ~434 and ~413 nm, 
respectively (Table 4-1). These values match that of Type II difference spectra indicating 
that the products are N-bound to the heme-Fe.8, 36, 41 Interestingly, although imidazoles are 
known to be potent inhibitors of most P450s, they are weak inhibitors of P450 BM3-HD, 
which has been attributed to P450 BM3-HD’s more rigid active site residues, as determined 
by solid-state NMR.8, 42 There is currently only one crystal structure of P450 BM3-HD 
with a simple imidazole and it is not with wild-type (wt) P450 BM3-HD, but with a mutant 
F87V form of P450 BM3-HD.9 As can be seen in Figure 4.19, the mutation of Phe to Val 
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allows for the binding of Im to the heme-Fe. Based on the overlay of wt and F87V P450 
BM3-HD, the distance between the nearest carbons of F87 and Im is 1.7 Å which is likely 
to cause clashing, leaving Im unstable in the active site. This could explain the difficulty 
in obtaining ferrous P450 BM3-HD-imidazole crystal structures. 
 
 
Figure 4.19. Overlay of the active sites and I-helix of wt P450 BM3-HD-palmitoleic acid 
(cyan; PDB id: 1FAG) and F87V P450 BM3-HD-Im (grey; PDB id: 4KF2). Palmitoleic 
acid is not shown for ease of viewing and Im is shown in magenta. 
 
 Locuson, et al. published a study in 2007 discussing the “incomplete” heme 
coordination of imidazoles with P450 3A4 and 2C9 after observing that their calculated 
difference spectra consistently had a significant shoulder at ~390 nm (Figure 4.20A).36 
Typically, N-containing ligands such as imidazoles react with the heme-Fe and help to 
stabilize low-spin Fe, but a shoulder at ~390 nm likely indicates that there is still some 
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high-spin Fe remaining after the reaction is complete. The same trend was observed for all 
reactions of ferric P450 BM3-HD with imidazoles (Figure 4.20B), however the shoulder 
for ferric P450 BM3-HD is drastically reduced as compared to that of P450 3A4. Therefore, 
it is likely that there is a much smaller amount of high-spin Fe present. 
 
 
Figure 4.20. (A) Calculated difference spectrum of the reaction between P450 3A4 and 
imidazole-based ligands.36 The Im reaction is indicated with a solid line. (B) Calculated 
difference spectrum of the reaction between P450 BM3-HD and Im. Arrows indicate a 





4.4.3 Formation of -bonded aryl-iron complexes 
 As was observed for the interaction of ferric P450 BM3-HD with imidazoles, upon 
addition of arylhydrazines, the Soret peak shifted from 418 to 421 nm (Figure 4.13A) 
indicating ligand binding at the heme-Fe (first step in Figure 4.21). Under aerobic 
conditions, as more oxygen (from air) enters the reaction, an aryl radical is formed which 
can react with the now oxidized ferric heme-Fe.43 This was observed in my UV-vis spectral 
studies as the peak at 421 nm decreased simultaneously with an increase in a 480 nm peak 
(Figure 4.13B). A max from 470-480 nm is indicative of a -bonded aryl-iron complex 
(second step in Figure 4.21)23, therefore it is likely that the identity of the products in the 
above UV-vis spectral studies are -bonded aryl-iron complexes as well. Similar results 
were produced in microsomal P450’s in their reaction with PhHZ, further justifying P450 
BM3-HD as a model P450.44  
 
 
Figure 4.21. Reaction mechanism of P450 BM3-HD with arylhydrazines (NH2NH-Ar). 
 
 Since the UV-vis spectral shifts match those of other previously published studies, 
it can be inferred what the identities of the ferric P450 BM3-HD-aryl complexes are. The 
first crystal structure of a hemoprotein-aryl derivative was published in 1984, and describes 
a Mb-phenyl complex resulting from the reactions of Mb with PhHZ.45 More recently, Dr. 
Bing Wang of our lab published four crystal structures of H64A and H64Q Mb after 
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reaction with 3-MePhHZ and 4-ClPhHZ.46 Only one ferric P450-aryl crystal structure has 
been reported which is a P450cam-phenyl structure resulting from reaction with 
phenyldiazene.25 The structure of P450 BM3-HD-aryl would likely resemble that of 
P450cam as their active site makeups are similar (Figure 4.22). Additionally, based on Dr. 
Wang’s recent work, it is known that the aryl-carbon that will bind to the Fe is the carbon 
that was initially bonded to the hydrazine group.46 
 
Figure 4.22. Alignment of P450cam-phenyl (grey; PDB id: 1CP4) with wt P450 BM3-HD 
(pink; PDB id: 1FAG). Residues are listed as P450 BM3-HD/P450cam. 
 
 If further oxidation of the FeIII to FeIV were to occur, this would induce a shift of 
the aryl group from the heme-Fe to one of the heme N-atoms (final step in Figure 4.21).23 
Unique to P450s is that the Fe to nitrogen shift can take place within the active site pocket 
without damage to the protein itself, making arylhydrazines useful probes for active site 
chemistry.23 Various studies have been published with various P450s to identify which of 
the four heme N-atoms the aryl group migrates to, by isolating the modified porphyrin and 
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subjecting it to HPLC separation. In the case of P450 BM3-HD, upon reaction with 
phenylhydrazine, a NB:NA:NC:ND ratio of 2:9:2:1 was obtained (see Figure 4.23A for 
naming scheme).26 This indicates that the area distal to NA in the active site is likely the 
most open for ligand binding (Figure 4.23B). Looking at the published X-ray crystal 
structure of P450 BM3-HD in complex with 1,2-ethanediol and polyethylene glycol (PEG) 
(PDB id: 4ZFA)47, the volume above the heme correlates very well with the HPLC results 
as the largest cavity is above NA (Figure 4.23C). 
 
 
Figure 4.23. (A) Heme pyrrole nomenclature. (B) HPLC results suggest that the area 
distal to NA in P450 BM3-HD is likely the most open for substrate binding. This area is 
indicated by a box (modified from Tuck, et al26). (C) The interior cavities (grey) of P450 
BM3-HD with 1,2-ethanediol and PEG (PDB id: 4ZFA) is shown. 
 
 In my studies, I used PhHZ, 3-MePhHZ and 4-ClPhHZ. In the future, porphyrin 
isolation and HPLC (as done by Swanson, et al.48) could be used to identify the porphyrin-
N migration ratios for these three ligands. The ratio would likely vary between the three 
ligands as the bulk and location of the aryl-substituent changes.  
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4.4.4 Future Work 
4.4.4.1 FTIR spectroscopy with P450 BM3-HD and RNOs 
Since attempts at crystallizing ferric P450 BM3-HD have thus far not been 
successful, a different method must be used to monitor the structural changes occurring in 
ferric P450 BM3-HD upon ligand binding. Fourier Transform Infrared (FTIR) 
spectroscopy can be used to detect changes in secondary structure. This is done by 
monitoring the amide I (1700-1600 cm-1), amide II (1600-1500 cm-1) and amide III (1220-
1320 cm-1) bands.49 The amide I band corresponds to C=O stretching which is weakly 
coupled with C-N stretching and N-H bending, the amide II band corresponds to C-N 
stretching which is strongly coupled with N-H bending and the amide III band corresponds 
to N-H in-plane-bending and C-N stretching vibrations.49, 50 Most commonly, the amide I 
and III bands are used to diagnose structural changes as the amide II band is not very 
sensitive to these changes.50 Additionally, for heme proteins, the porphyrin vinyl groups 
have a signal at ~1640 cm-1 (C=C stretch) which overlaps with the amide I band, but the 
signal between ~1740 and 1725 cm-1 (propionate C=O stretch) can be seen.51 
 
Figure 4.24. FTIR spectrum of ferric P450 BM3-HD. Conditions: 0.2 mM P450 BM3-
HD in 100 mM sodium phosphate at pH 7.4 
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For this study, structural changes upon binding of RNOs to ferric P450 BM3-HD 
would be measured. The reaction between ferric P450 BM3-HD and RNOs would be 
carried out using their RNO2 precursors similar to the UV-vis studies performed (See 
Section 4.2.3.1). If binding does not occur or the RNO2 is in excess, signals would be 
observed at 1600-1530 cm-1 and 1390-1300 cm-1 for alkyl RNO2 and at 1550-1490 cm
-1 
and 1355-1315 cm-1 for aromatic RNO2.
52 If the RNO2 is reduced to RNO and binds to 
ferric P450 BM3-HD, signals should be seen at or below ~1550 cm-1 corresponding to 
ferrous FeII-RNO.51 A preliminary FTIR spectrum of ferric P450 BM3-HD has been 
obtained using a Bruker Tensor-II equipped with an attenuated total reflectance (ATR) cell 
(Figure 4.24). The secondary structure breakdown matches with the PDBsum results (54% 





4.4.4.2 Extension to human P450s 
 Our goal is to eventually extend these studies to human P450s. CYP1A2, 2A6 and 
3A4 are located in the liver and are some of the major contributors known to metabolize 
xenobiotics. Combined, these three P450s are responsible for ~50% of the total 74% of 
xenobiotic metabolism performed by P450s in the body.2 This makes CYP1A2, 2A6 and 
3A4 the most relevant for us to work with. 
We were gifted the plasmids for P450s 1A2, 2A6 and 3A4 from Dr. Peter 
Guengerich at Vanderbilt University. In collaboration with my lab colleague, Viridiana 
Herrera, we successfully cloned the non-transmembrane portion of all three P450s and 
added a His-tag following published procedures.54-56 All three P450s were successfully 
expressed. Initial efforts were made to purify the proteins using Ni-NTA columns which 
showed promising results. However, in order to improve the purification and the solubility 
of the proteins, detergent screening needs to be completed. Thus far, the only detergent that 





 In this chapter, I have presented a spectroscopic analysis of the interaction of the 
heme domain of cytochrome P450 BM3-HD with C-nitroso compounds, imidazoles and 
arylhydrazines. It has been shown that C-nitroso compounds bind to ferric P450 BM3-HD 
in the N-binding mode and that the alkyl group size affects the extent of formation of the 
resulting complexes. Imidazoles were shown to bind ferric P450 BM3-HD in a Type II 
manner and, based on published work, are likely N-bound. Additionally, Phe87 likely plays 
a role in the binding of both C-nitroso compounds and imidazoles. Finally, the binding of 
arylhydrazines to ferric P450 BM3-HD was discussed. Initially, arylhydrazines interact 
with ferric P450 BM3-HD in a Type II manner, but under aerobic conditions, the aryl 
radical that forms, binds to the heme-Fe forming a -bonded aryl-iron complex. This work 
shows that P450 BM3-HD works well as a model system for P450 interactions with C-





[1] Hannemann, F., Bichet, A., Ewen, K. M., and Bernhardt, R. (2007) Cytochrome P450 
systems - biological variations of electron transport chains, Biochim Biophys Acta 
1770, 330-344. 
[2] Guengerich, F. P. (2015) Human cytochrome P450 enzymes, In Cytochrome P450: 
Structure, Mechanism, and Biochemistry (Ortiz de Montellano, P. R., Ed.) 4 ed., 
Kluwer Academic/Plenum Publishers, New York. 
[3] Munro, A. W., and Lindsay, J. G. (1996) Bacterial cytochromes P-450, Mol Microbiol 
20, 1115-1125. 
[4] Narhi, L. O., and Fulco, A. J. (1986) Characterization of a catalytically self-sufficient 
119,000-dalton cytochrome P-450 monooxygenase induced by barbiturates in 
Bacillus megaterium, J Biol Chem 261, 7160-7169. 
[5] Munro, A. W., Leys, D. G., McLean, K. J., Marshall, K. R., Ost, T. W. B., Daff, S., 
Miles, C. S., Chapman, S. K., Lysek, D. A., Moser, C. C., Page, C. C., and Dutton, P. 
L. (2002) P450 BM3: the very model of a modern flavocytochrome, Trends Biochem 
Sci 27, 250-257. 
[6] Ruettinger, R. T., Wen, L. P., and Fulco, A. J. (1989) Coding nucleotide, 5' regulatory, 
and deduced amino acid sequences of P-450BM-3, a single peptide cytochrome P-
450:NADPH-P-450 reductase from Bacillus megaterium, J Biol Chem 264, 10987-
10995. 
[7] Yeom, H., Sligar, S. G., Li, H., Poulos, T. L., and Fulco, A. J. (1995) The role of Thr268 
in oxygen activation of cytochrome P450BM-3, Biochemistry 34, 14733-14740. 
 
196 
[8] Haines, D. C., Chen, B., Tomchick, D. R., Bondlela, M., Hegde, A., Machius, M., and 
Peterson, J. A. (2008) Crystal structure of inhibitor-bound P450BM-3 reveals open 
conformation of substrate access channel, Biochemistry 47, 3662-3670. 
[9] Butler, C. F., Peet, C., Mason, A. E., Voice, M. W., Leys, D., and Munro, A. W. (2013) 
Key mutations alter the cytochrome P450 BM3 conformational candscape and remove 
inherent substrate bias, J Biol Chem 288, 25387-25399. 
[10] Luthra, A., Denisov, I. G., and Sligar, S. G. (2011) Spectroscopic features of 
cytochrome P450 reaction intermediates, Arch Biochem Biophys 507, 26-35. 
[11] Klingenberg, M. (1958) Pigments of rat liver microsomes, Arch Biochem Biophys 75, 
376-386. 
[12] Omura, T., and Sato, R. (1962) A new cytochrome in liver microsomes, J Biol Chem 
237, PC1375-PC1376. 
[13] Lee, J., Chen, L., West, A. H., and Richter-Addo, G. B. (2002) Interactions of organic 
nitroso compounds with metals, Chem Rev 102, 1019-1066. 
[14] Delaforge, M., Jaouen, M., and Mansuy, D. (1983) Dual effects of macrolide 
antibiotics on rat liver cytochrome P-450, Biochem Pharmacol 32, 2309-2318. 
[15] Mansuy, D., Rouer, E., Bacot, C., Gans, P., Chottard, J. C., and Leroux, J. P. (1978) 
Interaction of aliphatic N-hydroxylamines with microsomal cytochrome P450: Nature 
of the different derived complexes and inhibitory effects on monoxygenases activities, 
Biochem Pharmacol 27, 1229-1237. 
[16] Bensoussan, C., Delaforge, M., and Mansuy, D. (1995) Particular ability of 
cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon 
metabolic oxidation of aminodrugs, Biochem Pharmacol 49, 591-602. 
 
197 
[17] Mansuy, D., Beaune, P., Chottard, J. C., Bartoli, J. F., and Gans, P. (1976) The nature 
of the “455 nm absorbing complex” formed during the cytochrome P450 dependent 
oxidative metabolism of amphetamine, Biochem Pharmacol 25, 609-612. 
[18] Hackett, J. C., Kim, Y.-W., Su, B., and Brueggemeier, R. W. (2005) Synthesis and 
characterization of azole isoflavone inhibitors of aromatase, Bioorg Med Chem 13, 
4063-4070. 
[19] Recanatini, M., Cavalli, A., and Valenti, P. (2002) Nonsteroidal aromatase inhibitors: 
Recent advances, Med Chem Res 22, 282-304. 
[20] Owen, C. P., Shahid, I., Lee, W.-Y., and Ahmed, S. (2010) Synthesis and biochemical 
evaluation of a range of (4-substituted phenyl)sulfonate derivatives of 4-
hydroxybenzyl imidazole-based compounds as potent inhibitors of 17α-
hydroxylase/17,20-lyase (P45017α) derived from rat testicular microsomes, Bioorg 
Med Chem Lett 20, 5345-5348. 
[21] Choudhary, G., and Hansen, H. (1998) Human health perspective of environmental 
exposure to hydrazines: A review, Chemosphere 37, 801-843. 
[22] Jonen, H. G., Werringloer, J., Prough, R. A., and Estabrook, R. W. (1982) The reaction 
of phenylhydrazine with microsomal cytochrome P-450. Catalysis of heme 
modification, J Biol Chem 257, 4404-4411. 
[23] Ortiz de Montellano, P. R. (1995) Arylhydrazines as probes of hemoprotein structure 
and function, Biochimie 77, 581-593. 
[24] Ortiz de Montellano, P. R. (1984) The inactivation of cytochrome P-450, In Annual 




[25] Raag, R., Swanson, B. A., Poulos, T. L., and Ortiz de Montellano, P. R. (1990) 
Formation, crystal structure, and rearrangement of a cytochrome P-450cam iron-
phenyl complex, Biochemistry 29, 8119-8126. 
[26] Tuck, S. F., Peterson, J. A., and Ortiz de Montellano, P. R. (1992) Active site 
topologies of bacterial cytochromes P450101 (P450cam), P450108 (P450terp), and 
P450102 (P450BM-3). In situ rearrangement of their phenyl-iron complexes, J Biol 
Chem 267, 5614-5620. 
[27] Li, H. Y., Darwish, K., and Poulos, T. L. (1991) Characterization of recombinant 
Bacillus megaterium cytochrome P-450 BM-3 and its two functional domains, J Biol 
Chem 266, 11909-11914. 
[28] Sevrioukova, I., Truan, G., and Peterson, J. A. (1996) The flavoprotein domain of 
P450BM-3:  Expression, purification, and properties of the flavin adenine 
dinucleotide- and flavin mononucleotide-binding subdomains, Biochemistry 35, 7528-
7535. 
[29] Sevrioukova, I., Truan, G., and Peterson, J. A. (1997) Reconstitution of the fatty acid 
hydroxylase activity of cytochrome P450BM-3 utilizing its functional domains, Arch 
Biochem Biophys 340, 231-238. 
[30] Di Nardo, G., Dell'Angelo, V., Catucci, G., Sadeghi, S. J., and Gilardi, G. (2016) 
Subtle structural changes in the Asp251Gly/Gln307His P450 BM3 mutant responsible 
for new activity toward diclofenac, tolbutamide and ibuprofen, Arch Biochem Biophys 
602, 106-115. 
[31] Quaroni, L. G., Seward, H. E., McLean, K. J., Girvan, H. M., Ost, T. W. B., Noble, 
M. A., Kelly, S. M., Price, N. C., Cheesman, M. R., Smith, W. E., and Munro, A. W. 
 
199 
(2004) Interaction of nitric oxide with cytochrome P450 BM3, Biochemistry 43, 
16416-16431. 
[32] Wagner, G. C., Perez, M., Toscano, W. A., and Gunsalus, I. C. (1981) Apoprotein 
formation and heme reconstitution of cytochrome P-450cam, J Biol Chem 256, 6262-
6265. 
[33] Wagner, G. C., Gunsalus, I. C., Wang, M. Y., and Hoffman, B. M. (1981) Cobalt-
substituted cytochrome P-450cam, J Biol Chem 256, 6266-6273. 
 [34] Copeland, D. M. A study of the interactions of nitric oxide and nitric oxide containing 
molecules with heme proteins. Ph.D. Dissertation, University of Oklahoma, Norman, 
OK, 2006. 
[35] Rogerson, T. D., Wilkinson, C. F., and Hetarski, K. (1977) Steric factors in the 
inhibitory interaction of imidazoles with microsomal enzymes, Biochem Pharmacol 
26, 1039-1042. 
[36] Locuson, C. W., Hutzler, J. M., and Tracy, T. S. (2007) Visible spectra of type II 
cytochrome P450-drug complexes: Evidence that “incomplete” heme coordination Is 
common, Drug Metab Dispos 35, 614-622. 
[37] Yi, J., Ye, G., Thomas, L. M., and Richter-Addo, G. B. (2013) Degradation of human 
hemoglobin by organic C-nitroso compounds, Chemical Communications 49, 11179-
11181. 
[38] Word, J. M., Lovell, S. C., LaBean, T. H., Taylor, H. C., Zalis, M. E., Presley, B. K., 
Richardson, J. S., and Richardson, D. C. (1999) Visualizing and quantifying molecular 




[39] Fukuto, J. M., Brady, J. F., Burstyn, J. N., Van Atta, R. B., Valentine, J. S., and Cho, 
A. K. (1986) Direct formation of complexes between cytochrome P-450 and 
nitrosoarenes, Biochemistry 25, 2714-2719. 
[40] Mansuy, D., Beaune, P., Cresteil, T., Bacot, C., Chottard, J.-C., and Gans, P. (1978) 
Formation of complexes between microsomal cytochrome P-450-Fe(II) and 
nitrosoarenes obtained by oxidation of arylhydroxylamines or reduction of nitroarenes 
in situ, Eur J Biochem 86, 573-579. 
[41] Wilkinson, C. F., Hetnarski, K., Cantwell, G. P., and Di Carlo, F. J. (1974) Structure-
activity relationships in the effects of 1-alkylimidazoles on microsomal oxidation in 
vitro and in vivo, Biochem Pharmacol 23, 2377-2386. 
[42] Jovanovic, T., and McDermott, A. E. (2005) Observation of ligand binding to 
cytochrome P450 BM-3 by means of solid-state NMR spectroscopy, J Am Chem Soc 
127, 13816-13821. 
[43] Battioni, P., Mahy, J.-P., Delaforge, M., and Mansuy, D. (1983) Reaction of 
monosubstituted hydrazines and diazenes with rat-liver cytochrome P450, Eur J 
Biochem 134, 241-248. 
[44] Muakkassah, S. F., and Yang, W. C. (1981) Mechanism of the inhibitory action of 
phenelzine on microsomal drug metabolism, J Pharmacol Exp Ther 219, 147-155. 
[45] Ringe, D., Petsko, G. A., Kerr, D. E., and Ortiz de Montellano, P. R. (1984) Reaction 
of myoglobin with phenylhydrazine: A molecular doorstop, Biochemistry 23, 2-4. 
[46] Wang, B., Thomas, L. M., and Richter-Addo, G. B. (2016) Organometallic 
myoglobins: Formation of Fe–carbon bonds and distal pocket effects on aryl ligand 
conformations, J Inorg Biochem 164, 1-4. 
 
201 
[47] Geronimo, I., Denning, C. A., Rogers, W. E., Othman, T., Huxford, T., Heidary, D. 
K., Glazer, E. C., and Payne, C. M. (2016) Effect of mutation and substrate binding 
on the stability of cytochrome P450BM3 variants, Biochemistry 55, 3594-3606. 
[48] Swanson, B. A., Dutton, D. R., Lunetta, J. M., Yang, C. S., and Ortiz de Montellano, 
P. R. (1991) The active sites of cytochromes P450 IA1, IIB1, IIB2, and IIE1. 
Topological analysis by in situ rearrangement of phenyl-iron complexes, J Biol Chem 
266, 19258-19264. 
[49] Singh, B. R. (1999) Basic aspects of the technique and applications of infrared 
spectroscopy of peptides and proteins, In Infrared Analysis of Peptides and Proteins, 
pp 2-37, American Chemical Society. 
[50] Cai, S., and Singh, B. R. (1999) Determination of the secondary structure of proteins 
from amide I and amide III infrared bands using partial least-square method, In 
Infrared Analysis of Peptides and Proteins, pp 117-129, American Chemical Society. 
[51] Jung, C. (2008) Fourier transform infrared spectroscopy as a tool to study structural 
properties of cytochromes P450 (CYPs), Anal Bioanal Chem 392, 1031-1058. 
[52] Brown, J. F. (1955) The infrared spectra of nitro and other oxidized nitrogen 
compounds, J Am Chem Soc 77, 6341-6351. 
[53] de Beer, T. A. P., Berka, K., Thornton, J. M., and Laskowski, R. A. (2014) PDBsum 
additions, Nucleic Acids Res 42, D292-D296. 
[54] Sandhu, P., Guo, Z. Y., Baba, T., Martin, M. V., Tukey, R. H., and Guengerich, F. P. 
(1994) Expression of modified human cytochrome P450 1A2 in Escherichia coli: 
Stabilization, purification, spectral characterization, and catalytic activities of the 
enzyme, Arch Biochem Biophys 309, 168-177. 
 
202 
[55] Gillam, E. M. J., Baba, T., Kim, B. R., Ohmori, S., and Guengerich, F. P. (1993) 
Expression of modified human cytochrome P450 3A4 in Escherichia coli and 
purification and reconstitution of the enzyme, Arch Biochem Biophys 305, 123-131. 
[56] Nakamura, K., Martin, M. V., and Guengerich, F. P. (2001) Random mutagenesis of 
human cytochrome P450 2A6 and screening with indole oxidation products, Arch 




Appendix: General Scheme of Reactions 
 
Scheme 1. Reductive pathway for the reaction of Mb and Hb with RNO2 compounds. 
max values are shown below the scheme. 
 
 
Scheme 2. Oxidative pathway for the reaction of Mb and Hb with RNHOH compounds. 
max values are shown below the scheme. 
 
 
Scheme 3. Reductive pathway for the reaction of NRs with RNO2 compounds. max 








Scheme 4. Reaction of P450 BM3-HD with RNO2 compounds. max values are shown 
below the scheme. 
 
 




Scheme 6. Reaction of P450 BM3-HD with arylhydrazines. max values are shown below 
the scheme. 
 
